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Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and
immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure
in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs
in combination to improve responses to overcome the resistance, to potentiate the action of immune system with
the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a
particular therapy represent new concepts and approaches in the clinical management of melanoma. The third
“Melanoma Research: “A bridge from Naples to the World” meeting, shortened as “Bridge Melanoma Meeting” took
place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular
profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies
into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage,
and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to
impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30
international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their
experience regarding the most recent advances in research and clinical management of melanoma patients.Introduction
The 3rd “Melanoma Research Bridge” meeting was held
in Naples on December 2 to 4th, 2012 (Figure 1). Four
topics were mainly discussed during the three-day mee-
ting: molecular advances and biomarkers, combination
therapies, novel concepts for integrating biomarkers and
novel treatments, and the relevance of biology of tumor
microenvironment to treatment of melanoma. In the* Correspondence: paolo.ascierto@gmail.com
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reproduction in any medium, provided the oropening lecture Natale Cascinelli discussed the history
of melanoma diagnosis and treatment. Following the
consensus conference among clinicians, surgeons, der-
matologists, and pathologists in 1967, the histopatho-
logic prognostic factors by Clark (1969) [1] and Breslow
(1970) were introduced to determine prognosis and
make decisions regarding surgical and adjuvant therapy
for patients with cutaneous melanoma. Since then, the
prognosis and treatment decisions regarding surgical
and adjuvant therapy for a patient with cutaneous mel-
anoma have been based on the current AJCC/UICC
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Figure 1 Faculty and some attendants of the Bridge meeting
in Naples.
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logical and morphologic analysis of the tumor tissue, the
anatomic site of origin, and assessment of local spread
using TNM staging procedures.
The most recent version of the AJCC (7th Edition)
recommended including mitotic rate into the staging
system as independent prognostic factor. The change
was approved by the UICC. However, histopathological
characteristics cannot always accurately predict who will
relapse and who will remain disease free. Therefore, add-
itional prognostic and predictive markers to determine
the potential for metastatic relapse at the time of diag-
nosis and to guide therapeutic decisions in adjuvant set-
tings even in early stage melanoma patients are urgently
needed. Recently, a new molecular classification of mela-
noma is evolving based on chromosomal aberrations,
gene mutations and signaling pathways activation that
underlies biologically distinct subsets of melanoma re-
quiring different clinical management. These approaches
have already been proven successful in development of
novel molecular diagnostics and importantly novel the-
rapy approaches for melanoma patients.
Melanoma has historically been refractive to chemo-
therapy which provided very low response rates and little
to no benefit in overall survival (OS). The meta-analysis
of different Phase II Cooperative Group trials in meta-
static Stage IV melanoma showed a median survival time
of 6.2 months, 25.5% of the patients alive at 1 year, and a
median progression free survival (PFS) of 1.7 months [2].
In recent years, multiple targeted and immune-based
therapeutic strategies have been investigated and led to
innovative therapeutic approaches in melanoma targeting
molecules within activated signaling pathways or the
regulatory molecules expressed on the cell surface of ac-
tivated T cells. The recent approval by the FDA of two
drugs for the treatment of metastatic melanoma, includ-
ing vemurafenib that targets the BRAF harboring V600E
codon mutation and the immune response stimulatorymonoclonal antibody (MAb) ipilimumab blocking CTLA-
4 on T cells can be attributed to an improved understand-
ing of the genetics of the disease and its immune micro-
environment, respectively.
Identification of oncogenic mutations in serine/threo-
nine (Ser/Thr) kinase BRAF resulting in valine to glu-
tamine substitution at codon 600 (V600E) in cutaneous
melanoma led to development of an effective inhibitors
and clinical trials with vemurafenib [3] and other BRAF
inhibitor dabrafenib [4]. Vemurafenib is the first BRAF
inhibitor developed and approved for the first and
second line treatment of metastatic melanoma patients
harboring BRAF V600 mutation. Treatment with
vemurafenib improved OS, PFS, and response rate (RR),
when compared with standard chemotherapy with
dacarbazine (DTIC), and showed a typical toxicity profile
with photosensitivity reactions, rash, elevated liver
enzymes and development of cutaneous squamous cell
carcinoma. Response to vemurafenib treatment results
in dramatic rates of initial tumor regression (most of
them disappear at the PET-CT scan) in about few weeks
and rapid but short lasting improvement of symptoms.
As demonstrated by phase III trial BRIM-3 treatment
with vemurafenib resulted in much better PFS compared
to standard chemotherapy (5.3 months in the vemura-
fenib group versus 1.6 months in dacarbazine group).
Overall, the introduction into the clinical practice of
vemurafenib as well as of the other recent drug targeting
kinases within key signaling pathways (MEK, KIT, alterna-
tive BRAF mutations, etc.) identified a critical role to the
assessment of the mutational status of these genes in mel-
anoma. Indeed, it is now mandatory to evaluate the BRAF,
NRAS and KIT mutational status, to choose the right
therapy for the individual patient. The challenge however
is availability of well validated and accurate tests that will
detect low level and all treatment-sensitive mutations.
Two antibodies that block cytotoxic T lymphocyte-asso-
ciated antigen 4 (CTLA-4) augmenting antitumor immun-
ity, have been evaluated in phase III clinical trials i.e.,
ipilimumab (Bristol-Myers Squibb) and tremelimumab
(MedImmune, Inc.). Ipilimumab, compared with vaccine
therapy or placebo, showed to improve overall survival
(OS) of metastatic melanoma patients, with a less impact
on responses and PFS. Another promising immunother-
apy strategy in melanoma is targeting programmed cell
death-1 (PD1) receptor on activated T cells or its ligand
PD-L1. Despite improvement in clinical responses with
these agents only a subset of patients benefit from CTLA-
4 blockade. To better control the response to these drugs
new parameters of response, the immune related response
criteria, an evolution of the RECIST criteria, and new pa-
rameters of management of the immune-related adverse
events (irAEs) or adverse events of special interest
(AEOSI) are required. Furthermore, biomarkers that can
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tools to help guide treatment decisions for these patients.
Thus the emerging era of a personalized approach to the
management of melanoma patients will require the
identification of the specific subset of melanoma based
on the driving mutations or immune response-based
biomarkers to design the best drug combination for the
individual patient.
Molecular advances and biomarkers
There is a great need to accurately establish diagnosis,
prognosis and to define the outcome of individual me-
lanoma patients but the existing clinicopathologic prog-
nostic factors are not always adequate. In addition,
predictive markers to determine the efficacy of treatment
at the time of diagnosis and to guide therapeutic deci-
sions for individual patients in adjuvant settings even in
early stage melanoma patients emerge as an integral part
of clinical management in melanoma. The focus of this
section was on emerging prognostic and predictive
biomarkers for melanoma as well as novel approaches
providing increased opportunities for clinical application
of individual markers or multimarker assays including
molecular profiling, immune monitoring and functional
multiparameteric assay.
Melanoma-associated antigen A3 (MAGE-A3) is a
member of MAGE cancer-testis multigene family is mel-
anoma-specific but is not expressed in normal cells. The
specific expression of MAGE-A3 on various tumors pro-
vides the opportunity for a specific targeted therapy such
as vaccines or adoptive T cell therapy and it serves as an
eligibility factor for such treatments as only patients with
melanoma expressing the antigen (MAGE-A3+) will be
selected for treatment. In addition, the specific expression
of MAGE-A3 gives the potential for limited off-target ef-
fects and no immune tolerance. MAGE-A3 antigen is
present in major tumor types, e.g., melanoma up to 76%,
multiple myeloma 60%, head and neck cancer 49%, lung
cancer 35%, and thus potentially multiple therapeutic indi-
cations exists for these tumors including vaccines or T cell
adoptive therapy targeting MAGE-A3 [5].
As demonstrated by pre-clinical research the MAGE-A3
protein is weakly immunogenic by itself, but formulation
with various immunostimulant is able to induce a stronger
immune response leading to improved protection against
tumour growth in selected preclinical models [6]. Seventy
five patients with unresectable stage III and IV M1a meta-
static melanoma were treated with MAGE-A3 vaccine for-
mulated with two different immunostimulants, AS02B
and AS15 in a Phase II (GlaxoSmithKline) clinical trial.
The AS15 containing formulation showed better immuno-
logical response as demonstrated by higher CD4+ count,
MAGE-A3 specific antibody titer and clinical activity. The
overall survival for the AS02B group of patients was19.9 months while it was 31.1 months for the AS15
treated group of patients (median follow up of 48 months).
Vaccine therapy was well tolerated with mostly grade 1
and 2 toxicities and no noticeable difference in toxicity
was observed between AS15 and AS02B groups. No signs
of autoimmunity were observed [7].
Gene expression profiling using Affymetrix HG-U133
Plus 2.0 microarray platform was used to identify a sig-
nature predictive to the clinical benefit of the MAGE-A3
vaccine treatment using pre-treatment tumor biopsies. A
gene signature classifier based on differentially expressed
genes was identified. In fact, overall survival in patients
stratified by gene signature (GS) positivity was better
than overall survival in the non-responder subgroup.
Canonical pathway analysis of relevant genes identified
immune related signature including genes for antigen
presentation, protein ubiquitination and Interferon (IFN)
signalling suggesting that the presence of immune ef-
fector cells in the tumor microenvironment predicts
clinical benefit in response to treatment with MAGE-A3
vaccine [8]. Prospective validation of the signature is
under evaluation in a pivotal phase III trial DERMA trial
with MAGE-A3 vaccine as an adjuvant treatment for
resected IIIB and IIIC melanoma patients (with macro-
scopic lymph node) (1300 patients planned) and tests
whether pre-selection of patients with this GS would
allow for enrichment of patients with higher likelihood
of response to MAGE-A3 vaccine treatment.
Examples of tumor antigens similar to MAGE-A3 in-
clude other Cancer/Testis antigens such as NY-ESO-1
and frequently mutated antigen TP53 that are immuno-
genic only in cancer patients. Various methods are avail-
able to identify immunogenic antigens and rationally
design optimally effective cancer vaccines. Serological
expression cloning (SEREX) and antibody profiling of
protein arrays (Seromics) are tools for the discovery of
immunogenic tumor antigens. Spontaneous antibody
(Ab) titers against various tumor antigens have been
detected in the serum of melanoma patients, non-small
cell lung cancer patients and many other cancer types,
but not in healthy donor sera can also serve as tumor
biomarkers. Correlation of NY-ESO-1 serum antibody
with clinical course following anti-CTLA-4 treatment
with ipilimumab has been also established [9]. Melan-
oma patients seropositive at baseline for NY-ESO-1 have
a better response rate and outcome than baseline NY-
ESO-1 seronegative patients after ipilimumab treatment.
After local irradiation and ipilimumab treatment in a
melanoma patient, there are changes observed in NY-
ESO-1 immunity. Some 40 clinical trials centered on
NY-ESO-1 within the Cancer Vaccine Collaborative
(CVC) research program established at the Ludwig Insti-
tute (New York) in different types of cancer have been
completed or are ongoing [10].
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to induce high quality immune responses when they fail to
happen spontaneously. It is very important of characterize
the mechanisms leading to spontaneous immunity against
tumor antigens, and spontaneous immunity can be modu-
lated with immunotherapy (e.g., ipilimumab, and possibly
vaccines). The future of immune therapy will combine
vaccines that stir the immune system toward the specific
tumor antigen with nonspecific modulators of immune
suppression such as anti-CTLA-4 or anti-PD1, as well
as other drugs that broadly stimulate an array of im-
mune cells including antigen-presenting cells (APCs).
One promising group of immunomodulators is the Toll
like receptors (TLR) agonists such as Cytosine phos-
phate Guanine (CpG) oligonucleotides that has strong
immunostimulatory properties.
To inform on antigen heterogeneity and local respon-
sive/suppressive environment, it will be very important
to measure immune biomarkers in the periphery. These
multiple sources of heterogeneity suggest that the the-
rapy should be consistent with testing of tumor phe-
notype and specific antigen expression in individual
patients as well as their immune profile. Novel approaches
for detection of circulating tumor cells, circulating DNA,
exosomes are explored to detect phenotypic characteristic
of tumor cells that express specific combination of surface
markers, driver mutations or tumor derived products as
well as for immune-response monitoring.
Expression of a subset of chemokine genes is associ-
ated with presence of CD8+ T cells in melanoma metas-
tases, so that is possible to identify patients with clinical
benefit from vaccines. In fact, the “inflamed” tumor gene
expression profile also may be associated with clinical
benefit to ipilimumab. Two broad categories of melan-
oma metastases can be selected, according to gene ex-
pression profiling and confirmatory assays identifying a
T cell “poor” and a T cell “rich” group. The possibility
that a T cell-inflamed tumor microenvironment may be
a predictive biomarker for clinical benefit from vac-
cination is being tested prospectively in the GSK-Bio
MAGE-A3 vaccine trials. Innate immune “sensing” of
tumors appears to occur via an endoplasmic reticulum-
associated molecule referred to as STING (stimulator of
IFN genes)-dependent pathway and host type I IFN re-
sponse. “Inflamed” tumors likely are not rejected due to
dominant immune suppressive mechanisms, including
indoleamine 2, 3, dioxygenase (IDO), PD-L1, T regula-
tory cells (Tregs), and T cell-intrinsic anergy. Impor-
tantly, all of these are being targeted therapeutically in
early phase clinical trials. Combinatorial blockade of se-
lected inhibitory pathways is therapeutically synergistic
in preclinical models in vivo. Increased PD-L1, IDO, and
Tregs in the tumor site are driven by CD8+ T cells in
the tumor microenvironment. A new set of surfacemarkers driven by early growth response gene (EGR2)
that is a transcriptional target in T cell anergy may pro-
vide a strategy for identifying intrinsically dysfunctional
CD8+ T cells from tumors, and may also be thera-
peutic targets.
Three drugs are currently approved for immunotherapy
in melanoma: Interferon is the only approved agent for
the adjuvant therapy of melanoma, while ipilimumab is
approved for metastatic melanoma as first and second line
in US and second line in Europe. Interleukin-2 (IL-2) is
approved for metastatic melanoma but is not currently in
use in Europe. The mechanism by which IFN exerts an
antitumor effect has long been debated. The immuno-
modulatory role of IFN is unclear, but it modulates the
immune response, and has anti-proliferative, anti-vascular
and pro-apoptotic effects. Type I IFNs (alpha and beta)
promote proliferation and clonal expansion of CD4 and
CD8 T cells, enhance antibody production of B cells, in-
crease cytotoxic activity of natural killer cells (NK) and
CD8 T cells and have negative effects on the activation
and proliferation of Tregs.
Attempts to identify patients who benefit from adju-
vant treatment with IFN have been undertaken almost
from the point of the discovery of IFN’s benefit but to
date the results of these efforts have largely been disap-
pointing. The identification of predictive markers that
permit selection of patients who are most likely to bene-
fit would allow us to avoid the toxicity of treatment, in
more than half of patients who are now offered this
therapy. As emerged from meta-analyses, subgroup ana-
lyses of randomized trials and translational research
studies pre-selection of patients is still controversial. The
Wheatley meta-analysis of 2007 [11] show 5-year relapse
free survival (RFS) and OS differences of 7% and 3%,
while the Mocellin meta-analysis of 2010 [12], analyzing
14 randomized controlled trials from 1990 to 2008 (8122
patients), showed that IFN statistically significantly im-
proved disease free survival (DFS) (Risk Reduction =
18%) and OS (Risk Reduction = 12%) as adjuvant therapy
for melanoma patients but no optimal IFN-α dose and/
or treatment duration or a subset of patients more re-
sponsive to adjuvant therapy was identified.
Most randomized controlled trials evaluating adjuvant
therapy with IFN used Breslow thickness and lymph
node invasion for staging. Subgroup analyses in rando-
mized controlled trials have been performed by stratifi-
cation according to clinical and/or pathological features
at randomization, not identical over time (as assessment
of risk evolved over time). Statistical analysis was
performed as specified (intent to treat population), while
subgroup analyses were not pre-specified (generally not
been appropriate as the statistical power of the studies
was based on the original overall trial analysis) and has
nonetheless been pursued within and across trials
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fined to one or another subgroup). For all of these rea-
sons data emerging from these trials were discordant.
Studies have been performed in tissue and peripheral
blood (DNA and serum) of patients receiving adjuvant
or neo-adjuvant treatment with IFN to evaluate immune
response correlating with clinical outcome. As an exam-
ple, 20 patients with palpable lymph node metastases
(AJCC stage IIIB and C) participated in a neo-adjuvant
study [13]. They underwent surgical biopsy at study
entry followed by complete lymphadenectomy after
induction treatment with high-dose IFN-α (HDI). This
study was designed to assess clinical and pathologic
responses after 4 weeks of therapy and immunohistoche-
mical evaluation of immune cell subsets and melanoma-
associated antigens. Clinical responders had significantly
greater increases in endotumoral CD11c+ and CD3+ cells
compared with non responders. No changes have been
found in the expression of melanoma-associated lineage
antigens, tumor cell proliferation, angiogenesis, or apop-
tosis were evident.
Additional study in an effort to understand the effects
of HDI in relation to the balance of phosphorylated sig-
nal transducer and activator of transcription (STAT)
pSTAT1 and pSTAT3 have been undertaken. STAT1 and
STAT3 were evaluated jointly as mediators of IFN-α ef-
fects in the setting of the prospective neo-adjuvant trial
[14]. The Janus-activated kinase/STAT pathway of IFN
signaling is important for immuneregulation and tumor
progression. STAT1 plays a prominent role in the ef-
fector immune response, whereas STAT3 is implicated
in tumor progression and down-regulation of the re-
sponse to type I IFNs. Double immunohistochemistry
(IHC) for pSTAT1 and pSTAT3 were performed on
paired fixed (9 patients) or frozen (12 patients) biopsies.
HDI was found to up-regulate pSTAT1, whereas it
down-regulates pSTAT3 and total STAT3 levels in both
tumor cells and lymphocytes. Higher pSTAT1/pSTAT3
ratios in tumor cells pretreatment were associated with
longer overall survival (p = 0.032). The pSTAT1/pSTAT3
ratios were augmented by HDI both in melanoma cells
(p = 0.005) and in lymphocytes (p = 0.022). Of the im-
munologic mediators and markers tested, TAP2 trans-
porter was augmented by HDI (but not TAP1 and MHC
class I/II) [14].
Serum multiplexed immunobead-based cytokine pro-
filing can be used to detect melanoma cells and select
patients who may be more susceptible to IFN. Powerful
high-throughput multiplex immunobead assay techno-
logy (xMAP, Luminex Corp.) was used to simultaneously
test 29 cytokines, chemokines, angiogenic as well as
growth factors, and soluble receptors in 179 patients
with high melanoma and 378 healthy individuals, parti-
cipating in E1694 study. IFN treatment was correlatedwith decreases in levels of vascular endothelial growth
factor (VEGF), epidermal growth factor (EGF) and hep-
atocyte growth factor (HGF) and increased levels of
anti-angiogenic IFN-γ inducible protein 10 (IP-10) and
IFN-α. Pretreatment levels of IL-1α, IL-1β, IL-6, TNF-α,
and chemokines MIP-1α and MIP-1β were found to be
significantly higher in the serum of patients with longer
RFS values [15].
Methylthioadenosine phosphorylase (MTAP) a house
keeping gene is constitutively expressed in most normal
cells and tissues. Loss of MTAP activity was related to
deletions in human chromosome 9p21, encoding the
tumor suppressor genes CDKN2A and CDKN2B, MTAP
and IFN alpha and beta and to epigenetic regulation by
promoter hypermethylation. In malignant melanomas,
selective deletions in this chromosomal region or pro-
moter hypermethylation are known to result in a loss of
MTAP protein expression. MTAP expression has signifi-
cant impact on STAT1 activity. Using tissue microarrays
assembling 465 nevi, primary melanomas and metastases,
the expression of MTAP was investigated. In subgroup
analysis of patients with tumor thickness of 1.5-4.0 mm
revealed a significant survival benefit from adjuvant IFN
treatment regarding RFS (p < 0.05) if MTAP expression
was observed in the primary melanoma. Patients with
STAT1 positive melanomas also tended to benefit from
IFN concerning RFS (p = 0.074) and showed a significant
benefit of OS (p < 0.05) [16].
Peripheral blood lymphocytes (PBL) from melanoma
patients have reduced phosphorylation of STAT1 upon
IFN-α stimulation, demonstrating a defect in Type I IFN
signaling. Such defects could be partially restored by
prolonged stimulation with IFN. Archived peripheral
blood mononuclear cells (PBMCs) from 14 Stage IIIB-C
melanoma patients pre and post treatment were ana-
lyzed for STAT1-Y701 phosphorylation (pSTAT1) levels
by phospho-flow cytometry. Significant increase in STAT1
activation in peripheral blood T cells, but not B cells, upon
IFN-stimulation was evidenced from Day 0 to Day 29.
Moreover this increase of pSTAT1 in peripheral blood
T cells also correlated with good clinical outcome. Be-
tween patients who showed increased pSTAT1 signaling
after HDI therapy, only those who displayed modest aug-
mentation had good outcome.
A multi-factorial genetic model for prognostic assess-
ment of high risk melanoma patients receiving adjuvant
IFN has been performed, analyzing data of 284 melan-
oma patients. In univariate analysis of five-marker geno-
typing signature was prognostic for melanoma overall
survival. This signature defines high and low risk groups
and it was shown to be an independent predictor of OS,
after controlling for stage [17].
Specific human leukocyte antigen (HLA) class I and II
antigens (eg., HLA-A1, HLA-A11, HLA-Cw7, and HLA-
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response to interferon therapy or overall survival of
patients with metastatic melanoma. A total of 284 high-
risk melanoma patients participating in a randomized
trial and 246 healthy controls were molecularly typed for
HLA class I and II [18]. Specific allele frequencies were
compared between the healthy and patient populations,
as well as presence or absence of these in relation to
recurrence. No allele was associated with absence of re-
currence of melanoma in patients receiving adjuvant
IFN therapy with the exception of HLA-Cw* 06; -posi-
tive melanoma patients who have better relapse-free and
overall survival. Alleles related to autoimmune disease
were also investigated and HLA-Cw* 06 allele also corre-
lated with psoriasis. In addition, the ulceration of pri-
mary tumor and the proinflammatory gene expression
profile in tumor can also be considered as a predictive
marker of response to adjuvant IFN therapy in melan-
oma patients. This could be probably due to the activity
of IFN in mediating the up-regulation of HLA class I on
melanoma cells, and ulcerated melanomas have been
demonstrated to present a high MHC class I expression.
In conclusion, the selection of patients for IFN therapy
should consider parameters as ulcerated primary melan-
oma which will be prospectivly validated in EORTC 18081
trial, evaluation of level of biomarkers such as STAT1 ↑,
STAT3 ↓, pretreatment levels of proinflammatory cyto-
kines, and patients with HLA Cw*06 polymorphism.
Several polymorphisms have been found within the
CTLA-4 gene were shown to have an association with
the development of autoimmune disease as Graves’s
disease, type 1 diabetes and Addison’s disease. Specific
CTLA-4 polymorphisms have previously shown an asso-
ciation with autoimmune symptoms and response to
ipilimumab (i.e., GG allele of JO30). GG is associated
with decreased expression of CTLA-4 upon T-cell acti-
vation and thus a higher proliferation of T-cells. Cohort
of 286 melanoma patients treated with high-dose adju-
vant IFN in a randomized trial and 288 healthy controls
were genotyped for six CTLA-4 polymorphisms previ-
ously suggested to be important, AG 49, CT 318, CT 60,
JO 27, JO30 and JO 31 [19]. Specific allele frequencies
were compared between the healthy and patient popula-
tions, as well as presence or absence of these in relation
to recurrence. Alleles related to autoimmune disease
were also investigated. No significant differences were
found between the distributions of CTLA-4 polymor-
phisms in the melanoma population compared with
healthy controls. Relapse free survival (RFS) and OS did
not differ significantly between patients with the alleles
represented by these polymorphisms. No correlation be-
tween autoimmunity and specific alleles was shown.
Ipilimumab, an anti CTLA-4 specific monoclonal anti-
body therapy, results in a durable clinical benefit for asubset of patients with refractory melanoma and has re-
versible mechanism-based side effects. Though, definite
correlates of clinical response are not established several
potential biomarkers of response positively correlate
with improved clinical outcome following ipilimumab
therapy. The absolute lymphocyte count (ALC) in pa-
tients who achieved clinical benefit from ipilimumab
had a greater mean increase in ALC after starting ther-
apy than patients who had progressive disease. In
addition, to efforts monitoring T cell subpopulations
during treatment with CTLA-4 blockade, characte-
rization of antigen specific antibody and T cell responses
has similarly led to associations between immunologic
changes and benefit from CTLA-4 therapy. Serological
studies have evaluated antibody responses against a
number of tumor associated antigens, including MAGE,
Melan-A, MART-1, gp-100, and Tyrosinase. Patients, who
had detectable humoral responses against the cancer-testis
antigen, NY-ESO-1 were more likely to experience clinical
benefit than those with negative antibody titer.
Gene expression analysis of flow-cytometry purified
CD4+ and CD8+ T cells was employed to assess gene
profiling changes induced by ipilimumab. Selected mole-
cules were further investigated by flow cytometry on pre,
3-month and 6-month post-treatment specimens.
Ipilimumab up-regulated Ki67 and ICOS on CD4+ and
CD8+ cells at both 3- and 6-month post ipilimumab
(p ≤ 0.001), decreased CCR7 and CD25 on CD8+ at
3-month post ipilimumab (p ≤ 0.02), and increased
transcription factor Gata3 in CD4+ and CD8+ cells
at 6-month post ipilimumab (p ≤ 0.001). Increased
EOMES+CD8+, GranzymeB+ EOMES+CD8+ and de-
creased Ki67+EOMES+CD4+ T cells at 6 months were
significantly associated with relapse (all (p ≤ 0.03). De-
creased Ki67+CD8+ T cells were significantly associated
with the development of irAE (p = 0.02). At baseline, low
Ki67+EOMES+CD8+ T cells were associated with relapse
(p ≤ 0.001), and low Ki67+EOMES+CD4+ T cells were as-
sociated with irAE ((p ≤ 0.008). Up-regulation of prolifer-
ation and activation signals in CD4+ and CD8+ T cells
were pharmacodynamic markers for ipilimumab. Ki67+
EOMES+CD8+ and Ki67+EOMES+CD4+ T cells at base-
line merit further testing as biomarkers associated with
outcome and irAEs, respectively [20].
A systems-level approach is required for comprehen-
sive understanding of the interconnected components,
pathways, and cell types associated with an immune re-
sponse. Single cell network profiling (SCNP), is a novel
platform for assessing and measuring immune function/
dysfunction at a “systems” level. SCNP is a multipara-
metric flow-cytometry based analysis that can simultan-
eously measure, at the single cell level, both extracellular
surface markers and changes in intracellular signaling
proteins in response to extracellular modulators [21].
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application of an external modulation informs on the
functional capacity of the signaling network which can-
not be assessed by the measurement of basal signaling
alone (e.g., hypo or hyper-responsiveness of a specific
pathway). In addition, the simultaneous analysis of mul-
tiple pathways in multiple cell subsets can provide
insight into the connectivity of both cell signaling net-
works and immune cell subtypes. The integration of four
different parameters makes SCNP technology unique:
First, the level of biologic resolution provided, i.e. single
cell level. In the SCNP assay, the measurements of post-
translational protein changes after exposure to extra-cel-
lular modulators (such as cytokines, chemokines and
pharmacologic agents) are made at the single cell level
since the technology is flow cytometry based; Second,
the type of assessment performed, i.e., cell function. Un-
like the “snapshot” view of cellular signaling provided by
measuring the basal or resting phosphorylation state of
an intracellular protein, the application of an extra-cellu-
lar modulation forces the intracellular signaling network
to respond, revealing dynamic information about the
way the network processes information. Thus, the func-
tional capabilities of key signaling networks can be com-
pared, for instance, between the cells of healthy
individuals and diseased patients, allowing detection and
characterization of signaling abnormalities associated
with disease or in the same patient over time (e.g., dis-
ease monitoring), allowing the identification of changes
associated with disease progression or with response to
therapeutic agents or between patients, allowing for pa-
tient stratification. Third, the type of measurement
performed, i.e., quantitative and multiplexed. Since dif-
ferent modulators can act on the same intracellular
pathways and, in heterogeneous tissues, on multiple cell
subsets at the same time, the SCNP approach allows
measurement in a quantitative fashion and simulta-
neously of changes in intracellular protein levels in
response to different modulators in different cell sub-
populations without the need for cell separating/sorting.
Finally but importantly, for such an approach to be use-
ful not only in the research context but also in a clinical
one (e.g., development of clinical actionable biomarkers
for disease status or response to treatment), it must be
highly repeatable and reproducible, meeting the regu-
latory standards of analytic validity [22]. This has
been recently achieved with coefficients of variations
(CV) of functional assays pathway stimulation rou-
tinely below 5%. Achieving this goal requires strict
instrument standardization and performance monitor-
ing, rigorous attention to sample quality and reagent
qualification, and the introduction of automation and
validated methodology and ad hoc informatics infra-
structure [22].When applied to pathways shown to be important in
disease pathology, this method of mapping signaling net-
works has potential applications in the development of
disease profiling, the identification of novel disease tar-
gets, predictive tests for therapeutic response and patient
selection and overall for improved efficiency of drug de-
velopment [23,24]. Recently, using this technology have
published a “map” of the healthy immune signaling net-
work, in which several age-associated signaling nodes
were identified in specific subsets of cells within PBMC
samples from healthy individuals [25]. These studies
underscore the potential utility of SCNP for immune
monitoring applications, as well as biomarker develop-
ment for immune-mediated diseases. To this regard, a
study which has direct relevance to the ipilimumab
mechanism of action since it examined CD4+ T cell sig-
naling in the context of CTLA-4 expression was
performed [26]. Results showed that signal transduction
activities differed between CTLA-4 defined CD4+ subsets,
and between healthy and melanoma samples. Further
studies are ongoing, which will expand on the biological
findings and assess the association between ipilimumab
response and signaling differences. Taken all together
these studies demonstrate the utility of SCNP for immune
monitoring and point to the promise of using this method
for cancer immunotherapy biomarker development.
Better methods to determine melanoma progression
would allow further improvements in the prognostic as-
sessment of melanoma patients. Importantly, the accur-
ate prognosis will benefit proper risk stratification of the
early stage melanoma patients for adjuvant treatment.
The diagnosis of primary cutaneous melanoma at the
pathological level can represent a daunting task. Several
features are used to diagnose melanoma, such as cyto-
logic atypia, maturation with descent, poor circumscrip-
tion, presence of mitoses, and asymmetry. However, the
pathologic diagnosis of melanoma remains challenging,
resulting in a high degree of inter-observer variability
Although traditional cancer diagnostics approaches in-
cluding histopathology and IHC will likely remain stand-
ard tools for the future the upcoming molecular analyses
might be incorporated in the context of these established
methods when the definite diagnosis cannot be reached.
They potentially might be systematically incorporated
and lead to improvement of the AJCC/IUCC system.
Different approaches are routinely explored for discov-
ery and validation of biomarkers to improve diagnosis,
classification and prognosis. Gene expression profiling of
a series of freshly acquired nevi, primary, and metastatic
melanomas identified differentially expressed gene sets
during melanoma progression, including nevus to pri-
mary melanoma, radial versus vertical growth phase
melanoma or primary vs. metastatic melanoma. These
differentially expressed genes were hypothesized to have
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nohistochemical analyses confirmed the differential ex-
pression of some of these markers.
A three-marker IHC-based prognostic assay in pri-
mary cutaneous melanoma developed and tested in a
cohort of 395 patients. The markers evaluated included
NCOA3 (nuclear receptor coactivator 3), RGS1 (regula-
tor of G protein signaling), and SPP1 (osteopontin), and
were scored both by a pathologist blinded to patient
outcomes on a 0–3 scale, and using a digital imaging
analysis. The outcome parameters evaluated were dis-
ease-specific survival (DSS, primary endpoint) & sentinel
lymph node (SLN) metastasis. Each marker alone had
been shown to significantly predict DSS and SLN status.
Marker expression was then validated in an independent
cohort of 141 cases from German Cancer Registry
(Heidelberg/Kiel cohort). The multi-marker score was
independently predictive of DSS in cohorts, surpassing
tumor thickness and ulceration. Ulceration, an estab-
lished prognostification factor for localized primary mel-
anoma that has been included to the AJCC synoptic for
microstaging of melanoma. Thus, the multi-marker
assay can be considered a very important prognostic fac-
tor to predict DSS and SLN metastasis [27].
More recent studies have focused on the role of the
pleckstrin homology domain-interacting protein (PHIP)
gene in melanoma progression. PHIP emerged as the
gene most highly expressed in melanoma metastases vs.
primary tumors. PHIP was initially identified through its
interaction with the pleckstrin homology domain of in-
sulin receptor substrate (IRS) proteins. While it has
demonstrated roles in Insulin-like Growth Factor (IGF)
signaling and glucose metabolism, a role in cancer had
not been previously reported [28]. Aberrant activation of
the IGF signaling Pathway has been demonstrated in dif-
ferent cancers, and for this reason it is a rational target
for anti-cancer therapy. IGF binding results in receptor
phosphorylation, creating binding sites for IRS docking
proteins. IRS activation subsequently recruits PI3K and
activates AKT, which has been shown to activate aerobic
glycolysis in tumor cells. Glycolytic pathway genes in
turn have been shown to be capable of promoting tumor
invasion and metastasis.
Based on recent analyses, PHIP can be considered a
novel marker and mediator of melanoma metastasis.
shRNA-mediated targeting of PHIP significantly reduced
murine and human melanoma invasion and metastasis.
PHIP mediated its pro-invasive effects by virtue of acti-
vating AKT. The prognostic role for PHIP in human
melanoma was demonstrated in a study analyzing a
cohort of 345 cases. There was a significant association
between PHIP levels and ulceration.
Genotypic analysis aimed to identify the molecular
subtypes of melanoma demonstrating activated PHIP,based in part on its activation of AKT. AKT activation in
melanoma is associated with NRAS mutation or BRAF
mutation and PTEN loss. It was hypothesized that if
PHIP expression is sufficient for AKT activation, then
high PHIP-expressing melanomas should not have mu-
tant NRAS or BRAF/PTEN mutants. The great majority
of high PHIP-expressing melanomas were devoid of
NRAS or double BRAF/PTEN mutants. Thus, PHIP
levels are enriched in triple negative (WT BRAF, NRAS,
and PTEN) and double negative melanoma (mutant
BRAF and WT NRAS and PTEN).
The PHIP gene normally resides on the 6q14 locus,
but in melanoma 6q loss has been reported. By fluores-
cent in situ hybridization (FISH) analysis, not only is the
PHIP locus preserved in melanomas, approximately 80%
of high PHIP-expressing melanomas had an increased
copy number. More recent analyses were presented indi-
cating a prognostic role for high PHIP copy number.
Data were presented from experimental models of mel-
anoma showing that suppression of PHIP results in re-
duced glycolysis, lower VEGF levels and decreased
tumor angiogenesis. On the basis of these results, a
model of ulceration development was presented in mel-
anoma in which PHIP activation results in activation of
the IGF1R pathway and AKT, ultimately resulting in in-
creased glycolysis, invasiveness, and angiogenesis,
resulting in increased capacity to develop both ulcer-
ation and metastasis.
Between the mechanisms of acquired (late) BRAF in-
hibitors (BRAFi) resistance, there is a predominance of
MAPK-reactivation. This can happen by RAS mutations,
MEK mutations, BRAF V600E/K splicing or amplifica-
tion. This phenomenon reflects the fact that effective
initial on-target MAPK pathway inhibition in the major-
ity of melanomas provides the selective pressure for the
tumors to re-activate a melanoma-addicted pathway. By
whole-exome sequencing, AKT gain of function muta-
tions were identified in a minority of melanoma with ac-
quired BRAF inhibitor resistance. These AKT mutants
conferred BRAF inhibitor resistance most potently in a
cells which only weakly upregulated AKT in response to
BRAF inhibition. Thus, AKT mutants amplify an adap-
tive response to BRAF inhibition. This adaptive AKT re-
bound in response to BRAFi is widespread early during
therapy. The landscape of acquired resistance is quite
heterogeneous but core pathways exist. In a single pa-
tient, both MAPK- and AKT-dependent mechanisms of
acquired resistance can concur.
Combination therapies
Combination therapies are the most promising approach
to add the therapeutic value to therapy with a single
drug. A major challenge for the combination treatment
in melanoma is to overcome intrinsic and acquired
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lying resistance is important in order to develop effective
personalized targeted strategies for individual patients’ as
multiple mechanisms or resistance develop during the
initial treatment. Also, microenvironmental factors and
immune response need to be considered in designing
appropriate treatment strategies and developing markers
predictive of response. In addition, the efficacy of the
treatment could depend on using sequential of combined
modalities. Finally, preclinical models and methods
concerning the profiling of individual tumors need further
improvement. Despite, these numerous challenges several
combination therapies for melanoma entered clinical
evaluation, as discussed during this session.
The prognosis of melanoma varies widely by stage and
for high risk surgically resected melanoma (AJCC stage
IIB and higher) the risk of recurrence and death exceeds
35-40% at 5 years. On the other hand, most of cases are
diagnosed at early stage and in this setting patients with
high risk of developing metastatic disease may benefit
from adjuvant therapy which presents the best opportun-
ity at curing melanoma at this time. Advanced melanoma
displays immunological tolerance and it is hypothesized
that the role of immunotherapy in the adjuvant setting
could be the greatest before immune tolerance is
established. Multiple clinical trials have been performed
with adjuvant IFN-α immunotherapy for resected mela-
noma, and 3 meta-analyses reviewing these trials have
been reported to date. The Mocellin meta-analysis of 14
trials reported 18% reduction in the risk of relapse and
12% reduction in the risk of death with the use of adjuvant
IFN overall [12].
While most IFN adjuvant trials in melanoma have
reported a RFS benefit, a significant impact on OS has
been reported only in the high dose IFN regimen as
tested in the E1684 trial. E1684 randomized high risk
melanoma patients after surgery to either observation or
treatment with HDI given intravenously, 5 days a week
for 4 weeks (induction) then subcutaneously at lower
dosage, 3 days a week, for 48 weeks (maintenance).
E1694 randomized patients to be treated with adjuvant
ganglioside GM2-KLH/QS-21 (GMK) vaccine for
96 weeks versus HDI. HDI demonstrated significant im-
provements on RFS and OS in the E1684 (versus obser-
vation) and E1694 (versus GMK). In E1684, at the
median follow up of 6.6 years, compared to observation,
there was a 33% reduction in the hazard of death in
favor of IFN 39% reduction in the hazard of recurrence
and the greater benefit was seen in patients with a high
tumor burden (N1-2b). In E1694, compared to the GMK
vaccine, there was 24% reduction in the hazard of mor-
tality and 25% reduction in the hazard of relapse, with
the greatest benefit seen in patients with a lower tumor
burden (T4, N-) [29].The EORTC 18991 trial hypothesized that prolonged
treatment with IFNα-2b is needed to obtain a maximal
anti-angiogenic effect, and thus has compared observa-
tion with an intended 5 years of maximally tolerable
doses of pegylated IFNα-2b (pFNα-2b) for patients with
resected, stage III melanoma (TxN1–2 M0). During the
first 8 weeks, pegylated IFNα-2b was administered at
6 mg/kg per week followed by 3 mg/kg per week main-
tenance therapy for up to 5 years. The study was
designed to measure changes in distant-metastasis-free
survival (DMFS) as the primary endpoint, and was
powered to detect a 9.75% absolute difference in DMFS
at 4 years. The study results were first reported in 2007
at a median follow up of 3.8 years and later updated in
2011 at a median follow up of 7.6 years [30]. Significant
RFS benefit from pIFNα-2b was consistently seen in the
study overall (HR = 0.82 in 2007 and 0.87 in 2011), while
there was no overall benefit seen in DMFS or OS. Strati-
fying patients by stage (N1 versus N2), patients with
microscopic nodal involvement (N1) derived significant
benefits in RFS and DMFS as reported in 2007; these
improvements were still seen in the updated report in
2011, but no longer statistically significant. Patients with
clinically detectable nodal involvement (N2) showed no
significant benefit in any endpoint. On the other hand,
further subgroup analysis showed that the greatest bene-
fit of pIFNα-2b was seen in the N1 subset with an ulcer-
ated primary with a median OS of > 9 years versus
3.7 years. The median duration for the induction phase
was 8 weeks, while the median maintenance duration
was 14.9 months. In addition, 31% patients discontinued
treatment owing to adverse events and 23% remained on
treatment in years 4–5; this proportion of treatment at-
trition due to toxicity is higher than the 10% reported in
E1694 [29].
Predictive markers of therapeutic benefit are needed to
accelerate progress in the adjuvant therapy of melanoma
to treat only those who would relapse and to treat only
those who have the capacity to respond. Biomarkers
could serve to select patients who would benefit from
treatment with IFN and to spare side effects of the treat-
ment for patients who are not likely to respond. Bio-
markers of risk & benefit that have been evaluated in
studies of adjuvant IFN include S100B, autoimmunity,
the proinflammatory cytokine profile in serum. Auto-
immunity was identified to be a predictive factor for re-
sponse in adjuvant treatment with IFN as demonstrated
by the presence of thyroid, anti-cardiolipins, anti-nu-
clear, and anti-DNA autoantibodies [31]. The HLA
genotype was also found to be a factor predicting recur-
rence in patients treated with IFN as an adjuvant. The
rate of relapse is significantly lower in patients with
HLA A33, B57, Cw03 and Cw06. Other immunomodu-
latory mechanisms of high-dose IFN are the increase of
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cells, the modulation of the STAT1/STAT3 balance in
both tumor cells and host lymphocytes, the change in
serum cytokine concentrations, and the normalization of
T cell signaling defects in the peripheral blood lym-
phocytes [32]. Candidate biomarkers linked to the
pro-inflammatory immune response and markers of im-
munosuppression as assessed in the tumor microenviron-
ment (TME) and in circulation may have therapeutic
predictive roles in relation to immunotherapy. E1609 al-
lows the essential linkage of these biomarkers between the
TME and the circulation supported by the common sys-
tems biology where we hypothesize that a baseline pro-in-
flammatory biomarker model/signature will be predictive
of therapeutic benefit.
Recently, it has been postulated that the effects of IFN
could be even related to the BRAF mutational status in
melanoma (Soldano Ferrone, unpublished). BRAF V600E
mutation-activated pathway is present in approximately
half of cutaneous melanomas. Although, BRAF inhibitors
induce rapid anti-tumor responses in about 50% of
patients many challenges still exist to optimize BRAFi-
based therapy. First, about 40% of patients do not re-
spond to BRAFi due to primary resistance. Second, only
about 5% of patients have complete responses. Third, the
median duration of response among responders is less
than 7 months (secondary resistance). These clinical
findings emphasize the need to design rational combina-
torial therapeutic strategies to increase the frequency of
complete responses and to improve the duration of re-
sponse to BRAFi therapy. In this regard we are testing
the hypothesis that the BRAFi and type I IFN-α combin-
ation is more effective than the individual agents in sup-
pressing human melanoma cell growth both in vitro and
in vivo.
The interaction of type I IFN with target cells is medi-
ated through a heterodimeric receptor composed of two
subunits referred to as IFNAR1 and IFNAR2 with the
binding of this receptor playing a key role in the
antiproliferative activity of type I IFN. The available evi-
dence in the literature argues for an IFNAR1 down regula-
tion in melanoma cells harboring a mutated active BRAF
[33]. This finding reflects an increased ubiquitination and
degradation of IFNAR1 by βTrcp2/HOS protein, an E3
ubiquitin ligase, which is induced by the BRAF-MAPK
signaling activity. This mechanism explains why inhibition
of the BRAF-MAPK signaling pathway by vemurafenib
upregulates IFNAR1 expression in melanoma cells with a
mutated active BRAF. Consequently, the combination of
IFN and BRAF inhibitor is much more effective as com-
pared to the two single agents in monotherapy, in cell
lines both sensitive and resistant to BRAF inhibitor. More-
over, the in vivo combination of IFN-α and BRAF inhibi-
tor obtained a significant survival prolongation of SCIDmice grafted with BRAF mutated cells, strongly suggesting
that metastatic BRAF-mutated melanoma patients
could benefit from the combination of IFN and BRAF
inhibitor treatment (Soldano Ferrone, unpublished).
Clinical trials are being implemented to test whether
the therapeutic efficacy of the BRAF-I and INF-α
combination is significantly higher than that of the
individual agents in patients with melanoma with
BRAF-mutation.
Another effect of this combination is the upregulation
of HLA Class I molecules as well as of antigen process-
ing machinery (APM) for melanoma antigens, inducing
a greater sensitivity to T cell recognition which supports
the rationale for the association with other immuno-
therapies such as anti-CTLA-4 treatment. In a Phase II
Trial, tremelimumab was tested in combination with
high-dose IFN-α yielded a high overall response rate.
Overall, 37 patients were treated with tremelimumab
given at 15 mg/kg every 90 days, and high-dose IFN-α
simultaneously given at standard FDA-approved doses
[34]. Among 35 evaluable patients, this therapy resulted
in 4 complete response (CR) and 5 partial response (PR)
(response rate, 24%), and 14 (38%) stable disease (SD);
median PFS was 6.4 months and median OS 21 months.
A rationale for a possible additional combination therapy
is based on the blockade of PD1-PDL1 interactions with
anti-PD1 or anti-PD-L1 mAbs, which enhance the cyto-
toxic function of HLA class I antigen restricted, tumor
antigen-specific T cells in vitro as well as with antitumor
effectors in the tumor microenvironment in vivo [35].
Since IFN induces tumor B7-H1 expression this provides
the basis for the combination of IFN and anti-PD1 treat-
ments. Concluding, IFN might have a role in rational
combinations with the new agents designed in a more or
logical sequence of drug administrations.
Various studies of combined treatment of chemother-
apy and cytokines have been conducted with contradict-
ory results. The phase II E4697 adjuvant trial for high
risk resected stage III-IV melanoma tested the hypoth-
esis that granulocyte macrophage colony-stimulating
factor (GM-CSF) and/or Tyrosinase peptide-based vac-
cine would be of therapeutic benefit. However, the trial
showed that neither GM-CSF nor peptide vaccination
achieved the objectives of significant improvement in
OS or DFS. A suggestion of a favorable effect of GM-
CSF on DFS and OS among Stage IV subjects was seen
at subset analysis that warrants further investigation
[36]. Recently, the study of Intergroup S0008 phase III
clinical trial has compared HDI versus Biochemotherapy
(BCT) [cisplatin, vinblastine, DTIC plus IL-2 and IFN]
as adjuvant treatment for patients with high risk melan-
oma. RFS at 5 years was 47% for BCT and 39% for HDI,
median RFS was 4.31 vs. 1.9 years, respectively, and OS
at 5 years 56% for both [37]. Significant differences in
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suggest that BCT is a valid alternative for adjuvant treat-
ment in patients with high risk melanoma.
Other adjuvant modalities evaluated were cellular vac-
cines: Canvaxin (was detrimental in Ph III trials),
MAGE-A3 peptide vaccination given in adjuvant with a
TLR-9 agonist (results are pending), and anti-CTLA-4
blocking monoclonal antibody therapy with ipilimumab
(EORTC 18071 and US Intergroup E1609 trials are still
pending). Adjuvant trials of BRAFi and BRAFi plus
MEKi are ongoing. EORTC 18071 trial randomized pa-
tients with resected stage IIIA, IIIB, IIIC melanoma, to
receive adjuvant ipilimumab at 10 mg/kg or placebo.
Intergroup E1609 Adjuvant Phase III trial randomizes
patients with resected stage IIIB, IIIC, M1a or M1b to
be treated with ipilimumab at 10 mg/kg or 3 mg/kg ver-
sus HDI.
The induction of an effective T cell mediated
antitumor response is dependent upon the encounter
of cytotoxic T-cells with their cognate antigen. How-
ever, the identification of tumor antigens that can
successfully mediate an effective antitumor response
with ACT immunotherapy requires more research. In
mice, the adoptive transfer of T cells specific for a
nonmutated melanoma differentiation antigen (gp100)
can mediate tumor regression of established B16 mur-
ine melanoma [38]. However, B16 does not harbor a
BRAF mutation and therefore does not model the hu-
man melanoma mutational landscape [39]; conse-
quently, established B16 tumors on C57BL/6 mice are
nonresponsive to vemurafenib therapy. Despite its ap-
propriateness as an antigenic system to evaluate “self-
reactivity” with gp100 T cell receptor (TCR)-specific
transgenic T cells, the efficacy of this sort of T-cell
mediated antitumor immunity may not translate well
into human clinical trials given the lack of B16 human
genetic relevance. Therefore, the development of rele-
vant BRAF V600E mutant murine melanoma trans-
plantable models that allow for high-throughput
antitumor efficacy testing in rodents could serve to nar-
row the existing “bench to bedside” translational gap.
The advent of modern genome-wide screening tech-
nologies has allowed more comprehensive understand-
ing of the genetic complexity of human melanoma
[39,40]. Common co-occurrence of BRAF mutations
with deletions of the PTEN tumor suppressor gene [39]
suggests a concerted biological contribution to melan-
oma development. Consistent with this observation,
transgenic mice engineered to express the BRAF V600E
oncoprotein on a PTEN deficient background develop
metastatic melanoma [41]. Established tumors from this
syngeneic BRAF V600E/PTEN−/− transplantable melan-
oma cell line are highly sensitive to orally administered
vemurafenib therapy on C57BL/6 immunocompetenthosts. The lack of gp100 expression recapitulates the
common intratumoral gp100 expression heterogeneity
observed in majority of patients with metastatic melan-
oma. Efficacy testing of vemurafenib in combination
with ACT immunotherapy using this relevant model,
did not improve the antitumor activity of adoptively
transferred gp100 TCR-specific T-cells. Given the add-
itional heterogeneity observed for other “self” melan-
oma differentiation antigens (MART-1, Tyrosinase) in
human melanoma, preclinical modeling of “non-self”
antigen reactivity becomes essential for the evaluation
of combinatorial immunotherapeutic modalities. In
addition, the development of antigenic systems that tar-
get the product of mutated genes may serve as definite
proof that neoantigens can mediate successful T-cell
antitumor responses against melanoma. Identification
of a tumor’s expressed mutated genes by whole-exome
sequencing, may allow prediction of mutant T cell epi-
topes that could be exploited to develop new preclinical
models of “non-self” antigen reactivity. Finally, appropri-
ate preclinical modeling of both in vivo sensitivity to
targeted therapy and antigen-specific immunity (“self” and
“non-self”), should better predict the clinical efficacy of
therapeutic regimens that combine targeted therapy (e.g.
vemurafenib) with a T-cell based immunotherapeutic
approach (e.g., ACT immunotherapy).
Adoptive cell transfer (ACT) immunotherapy proves
the concept of effective antitumor T cell mediated cyto-
toxicity and is the most effective form of immunother-
apy for patients with metastatic melanoma. Current
ACT clinical protocols using autologous TILs can medi-
ate durable complete responses in 22% of patients with
95% of patients surviving beyond 3 years [42]. Therefore,
combining two state-of-art-treatments i.e., vemurafenib
with adoptive cell transfer immunotherapy in patients
with advanced melanoma could prove more effective. It
has been reported that BRAF V600E inhibitor improves
recognition of human melanoma cells by antigen-spe-
cific T lymphocytes through increased expression of
melanoma differentiation antigens (MDAs) [43]. In
addition, improved tumor recognition is associated with
enhanced expression of MHC class I and biopsies of
melanomas treated with vemurafenib increases CD8+
T cell infiltrating the tumors. Preclinical studies have
also shown that the combination of agents that activate
T-lymphocytes such as agonistic antibodies to CD-137
in models of melanoma synergize with BRAF-inhibitors
to induce tumor regressions. Blocking activity of onco-
genic BRAF can also increase the expression of pro-
apoptotic Bcl-2 family members Bim and Bad potentially
lowering the intrinsic apoptotic threshold of the tumor
cells [44,45]. Furthermore, BRAF inhibition can decrease
the production of immune-suppressive cytokines by
tumor cells that might otherwise recruit regulatory
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that could hinder a T cell mediated antitumor response
[46]. This provides a strong rationale to combine anti
BRAF therapy with immunotherapy strategies.
BRAF mutations have been identified as the most fre-
quent in melanoma and development of BRAF inhibitors
for clinical setting has been extremely successful.
Vemurafenib is a “selective” BRAF Inhibitor of V600
mutant BRAF kinase in melanoma, with an optimal ac-
tivity at the dose of 960 mg twice daily (bid), as defined
by the phase I, II and III clinical trials. Based on the
Phase III trial comparing vemurafenib vs. DTIC 2011
vemurafenib was approved by the FDA [47]. Concomi-
tantly with the drug, companion diagnostic test that
can identify melanoma patients with BRAF V600E mu-
tation who most likely to benefit from this therapy was
also approved.
Despite the impressive single-agent clinical activity sev-
eral problems exist that need to be overcame to improve
the efficacy of vemurafenib i.e., toxicity of the drug, reacti-
vation of the MAPK pathway, development of resistance
and occurrence of the secondary tumors. Combination
regimens based on mechanisms of resistance and/or activa-
tion of oncogenic pathways that involve other therapeutic
targeting agents for melanoma (MEK, PI3K, AKT, CDK4/6,
Hsp90 etc.), are expected to have additive or synergistic
effects on clinical outcome when added to BRAF inhibitors.
Other promising avenues of melanoma drug develop-
ment include targeted to the host i.e., immunotherapy
(ipilimumab, anti-PDL1, pIFN). Another, possibility is anti-
angiogenic therapy (e.g., bevacizumab and IL-2) in combin-
ation with targeted therapy (BRAF, MEK, ERK etc.)
targeting the tumor.
Other tumors harboring BRAF mutations have also
been identified. For example, 10% of colon cancer (CRC)
population harboring BRAF mutation has extremely
poor prognosis. In the Phase I trial CRC expansion
cohort, activity of a single agent vemurafenib has been
disappointing (1 PR out of 20 total) [48], but recent pre-
clinical studies suggest, that combination of BRAF plus
EGFR inhibitors show strong synergy and may be more
effective. The strong synergistic effect between inhibition
of BRAF and EGFR is explained by a powerful feedback
activation of EGFR caused by BRAF inhibition [49].
These data explain poor clinical response of BRAF
V600E colon cancer to vemurafenib monotherapy and
provide a strong rationale for a clinical trial combining
vemurafenib plus cetuximab in CRC BRAF mutated pa-
tients. Vemurafenib has been effective in thyroid cancer
with V600 BRAF mutation (2 PR, 1 SD out of 3 total on
Phase I trial) and there is already a registration trial on-
going in papillary tumors [50]. Other tumor types have
also been shown to carry variable BRAF mutation rates
(LCH 60%, HCL 100%, NSCLC 2%, cholangiocarcinoma,breast, ovarian, germ cell etc.). Currently, there is an
open label Phase II trial designed to treat all BRAF-mu-
tated tumors (“BRAFomas”) [51] with the next step be-
ing to take the most promising leads from this trial to
registration or alternatively use this as a blueprint for
development of combination strategies.
However, it is virtually impossible to explore all poten-
tial drug combinations using tumor material before and
after tumor progression or performing sequential biop-
sies from the patients considering functional complexity
of the tumor and developing resistance. Model systems
to identify novel combination treatment for cancer are
lacking. Possible solutions are: to develop in vitro
models of resistance, develop tumor sampling tech-
niques (short term cultures, circulating tumor cells/
DNA), as well as use mathematical models based on in-
formation from patient tumors both at the time of diag-
nosis and at the time of ultimate resistance to predict
more efficacious combinations of existing drugs upfront.
In vitro models of resistance should allow for observing
dynamic changes in melanoma cells in the presence of
drugs or drug combinations and provide a better view of
drug response than static IC50 single end-point assays.
In melanoma cell lines, the response to vemurafenib is
different within seemingly isogenic cell lines as some
cells respond by entering quiescence, very few cells
undergo apoptosis (except in SK-MEL-5) and different
subpopulations of cells respond by varying levels of in-
hibition of proliferation rate [52]. The net result of the
response to vemurafenib is that after treatment the en-
tire population of tumor cells begins to rebind, thus
mimicking the resistant tumors developing in patients.
Another way to overcome limitations of serial tumor
biopsies is to obtain cells from patients for in vitro
assays based on circulating tumor cells (CTCs) or circu-
lating macromolecules that originate in tumor cells. If
the DNA/RNA corresponds to the changes observed in
individual tumors with sufficient accuracy, they should
facilitate detection of the molecular mechanism under-
lying resistance in individual patients. Novel models
mimicking the interaction of both tumor and stromal
populations, including TILs are needed. For example,
ex-vivo cultures that capture these interactions could
provide a system closer to individual tumor to optimally
guide new treatments and to predict the efficacy of com-
bination of new drugs for metastatic melanoma.
As with all tumors, clinical trials for melanoma are not
consistently conducted with a solid rationale from pre-
clinical animal efficacy studies. All preclinical models
have limitations and often fail to predict antitumor effi-
cacy in human clinical trials. Mouse models either
xenotransplanted or genetically-engineered completely
mimicking human melanoma biology are not available
and the use of immunodeficient hosts that do not allow
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the existing translational “bench to bedside” gap. New
models are required to develop predictors of response
and to establish combination molecular or/and immune-
based therapies since some combinations may be antag-
onistic or affect tumor infiltrating lymphocytes (TIL)
effector function.
Maximum BRAF V600E level reduction occurs during
Cycle 2 and 3 in vemurafenib treated patients as mea-
sured using RT-PCR based assay [53]. The same level of
reduction is observed later, in at least Cycle 4 in patients
treated with the combination of dabrafenib (BRAF in-
hibitor) and trametinib (MEK inhibitor) suggesting bet-
ter response to RAF +MEK combination in comparison
to BRAF alone [53]. The reduction of circulating mu-
tated BRAF level is also associated with tumor regres-
sion by RECIST. In addition, a detectable increase in
BRAF V600E level was seen ~50 days prior to radio-
graphic progressive disease in patients treated with
BRAF-directed therapy, thus potentially enabling an
early intervention to delay resistance [53]. If the mech-
anism of resistance can be identified before treatment or
early in the treatment the strategies can be developed to
use at the beginning of therapy.
The lessons learned from BRAF inhibitor development
lead us to conclusion that targeting mutated BRAF gene
in melanoma is a valid strategy, but not sufficient to im-
prove overall survival. Careful biochemical and genetic
analysis of the tumor samples and/or short term cultures
derived from patient’s tumors including stroma and TILs
may point to the useful combination treatments for indi-
vidual patients. Remaining challenges include proper
PK/PD investigations as part of Phase I studies of new
drug candidates to truly evaluate their therapeutic po-
tential. Importantly, correlative studies should be in-
corporated in the early drug development including
exploration of novel targets, developing resistance, com-
binatorial strategy testing, and dosing strategies. Com-
puter simulation studies of non-standard drug scheduling
may also help to move beyond simple sequential or com-
bination therapy to achieve the goal of improving patients’
outcome.
BRAF inhibitors have different effects in BRAF V600E
mutant melanoma and BRAF wild type cells. Reduction
of MAPK signaling and consequent block of the cell
proliferation in the V600 mutated melanoma cells
whereas activating MAPK signaling and progression
through the cycle cycle in cells harboring wild type
BRAF is observed. The evidence suggests that the use of
BRAF inhibitor alone leads to reactivation of the MAPK
pathway and enhances its activation through another
member of RAF family of kinases CRAF. This “paradox-
ical” MAPK activation by BRAF inhibitors can result in
the development of cutaneous squamous cell carcinomaof keratoacanthoma type (cuSCC/KAs), a typical cutane-
ous manifestation of BRAF inhibitor therapy such as
with vemurafenib or dabrafenib in ~25% of patients [54].
This suggested that combination of BRAF with MEK in-
hibitors might be preferred option as it might overcome
CRAF stimulation, prolong PFS and prevent the emer-
gence of squamous-cell carcinomas. Indeed, this com-
bination in BRIM 7 trial (GDC-0973/cobimetinib and
vemurafenib) resulted in preventing the emergence of
hyperproliferative skin lesions [55].
In preclinical mouse-models, cyclooxygenase 2 (COX2)
inhibitors prevent the formation of squamous cell carcin-
omas of the skin even in COX-2 deficient mice exposed to
DMBA and TPA, a commonly used skin carcinogenesis
mouse model. A hypothesis based on these results is that
the hyperactivation of COX-2 results in increased prosta-
glandin E2 (PGE2) level that activates PI3K and Src via G
protein coupled receptors EP2/4. PI3K and Src activate
HRAS and CRAF, and trans-activate EGFR that results in
the paradoxical activation of MEK, during the treatment
with vemurafenib. This was demonstrated in another mur-
ine preclinical model where COX-2 inhibition with COX-
2 inhibitor (celecoxib) blocked acceleration of DMBA/
TPA-induced skin tumor development by a BRAF in-
hibitor [56]. Another analysis of these murine models
showed that the addition of celecoxib decreased pMEK
and pERK levels. Further studies in a murine skin squa-
mous cell carcinoma cell line, PDV, showed that
vemurafenib-stimulated paradoxical growth of PDV
cells is inhibited by celecoxib.
As already discussed, vemurafenib was the first BRAF
inhibitor that show significant clinical benefit in mela-
noma patients. Treatment with vemurafenib leads to a
reduction in the level of phosphorylated MEK and ERK
in tumors containing mutated BRAF V600E which is as-
sociated with clinical response. BRAF inhibitors can
effectively inhibit 90-100% of MAPK signaling. This un-
derlies the rapid response and clinical effect of this class
of drugs on patients with BRAF V600 mutant melan-
oma. Importantly, it appears that the great majority of
patients treated with single BRAF inhibitor will eventu-
ally have progressive disease despite successful inhibition
of the V600E BRAF and high objective response early in
the course of therapy. ERK (and MEK) phosphorylation,
Cyclin D1, and Ki-67 are again upregulated in samples
taken at the time of progressive disease as compared to
their reduced expression early in therapy.
Available data suggest that the resistance to vemurafenib
is not related to the development of secondary “gate-
keeper” mutations of BRAF V600E gene that prevents the
binding of the treatment drug to BRAF. In fact, a large
number of resistant melanoma samples have had entire
BRAF gene sequenced and no secondary mutation were
found. Instead the resistance is mediated by reactivation
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mechanism. Several mechanisms of acquired resistance to
BRAF inhibition have been identified including: ac-
quisition of NRAS and MEK1 activating mutations,
upregulation of receptor tyrosine kinases (i.e., PDGFRB,
ERBB2), PTEN loss, activation of the Ser/Thr MAPK ki-
nases (COT), NF1 loss, BRAF truncations, BRAF amplifi-
cation and possibly others. All of these mechanisms
involve the reactivation of the MAPK pathway [57]. In
addition, signalling through the PI3K pathway involving
PI3K and AKT through the IGF1R signalling represents
an alternative mechanism of acquired resistance. Studying
resistance to BRAF inhibitors has also shown that HGF
levels can be increased in primary and acquired resistance.
Results from the Sequenom Oncocarta Panels, performed
prior to therapy with BRAF inhibitors, NRAS, and BRAF
mutations co-occurred at very low frequency (1% or less).
Whereas, in lesions from progressing patients, mutations
in NRASQ61 and BRAF V600 co-occur in up to 30% sam-
ples. Another mechanism of resistance to BRAF inhibitor
can be an alternate splicing of V600E RNA. This emerges
from the data of the biopsies performed on metastatic
melanoma patients progressing during anti-BRAF therapy.
On 21 patients tested at progression, 10 had either BRAF
splice variant or NRAS mutation. In addition, PLX4720
enhances the levels of the anti-apoptotic BCL-2 family
member protein MCL-1 in NRAS mutant melanoma
cells through enhanced signaling through the MAPK
pathway [58].
Primary resistance to BRAF inhibition is present in ap-
proximately 5-10% of patients with BRAF mutant melan-
oma patients including CCND1 amplification in tumors,
leading to downstream over expression of Cyclin D1 and
enhanced CDK4 expression. CTNNB1 mutations co-oc-
curred pre-therapy and at progression at ~5-10% fre-
quency. Sanger Sequencing (exons 2, 3 and 6) of MEK1
demonstrate, MEK1P124 mutations co-occur at low fre-
quency (6/132 pts, ~7%) with BRAF V600 mutations prior
to treatment. Rare MEK1 mutations (codons 56, 121, and
203) that are known to reactivate MAPK pathway and be
resistant to MEK1 inhibitors have been identified at pro-
gression. These might represent pre-treatment markers of
resistance which can help to identify patients who are not
likely to respond to BRAF inhibitors.
Recent RNA interference screen showed that neuro-
fibromin (NF1) drives resistance to BRAF inhibition
[59]. The NF1 gene encodes the tumor suppressor gene
that inhibits NRAS activity. Loss of function mutations
in NF1 results in the sustained activation of MAPK
pathway by increasing RAS signaling, which renders
cells resistant to RAF and MEK inhibitors. The study in
samples from patients with melanoma who received
BRAF inhibitor therapy suggested a role for NF1 in both
intrinsic and acquired drug resistance. Whole-exomesequencing of pre-and post-treatment samples identified
4 patients with NF1 mutations in both pre- and post
treatment specimens. IHC studies demonstrated that 2
of 5 expressed little or no protein before BRAF treat-
ment. In the remaining 2 of 3 with initial neurofibromin
expression, vemurafenib treatment was associated with
loss of protein expression [60]. This study provides new
insight into melanoma progression and suggests novel
therapeutic strategies for mutant BRAF/NF1-deficient
melanomas.
Another novel approach to melanoma treatment under
investigation is the use of oncolytic viruses (OVs). OVs
are native or recombinant viral vectors that mediate host
anti-tumor activity through two distinct mechanisms
[61]. First, these viruses enter cells and selectively repli-
cate in tumor cells resulting in lytic cell death. Second,
the viral infection and dying tumor cells induce a host
anti-tumor immune response. To date, the pox and her-
pes viruses have been most extensively studied in pre-
clinical models and in melanoma clinical trials. Vaccinia
virus is the prototypical poxvirus and has been exten-
sively used to express tumor-associated antigens and im-
mune potentiating factors as vaccines in a variety of
different cancers [62]. Recombinant Vaccinia viruses en-
coding the human B7.1 T cell co-stimulatory molecule
alone or in combination with intra-cellular adhesion
molecule 1 (ICAM-1) and leukocyte function associated
antigen-3 (LFA-3) was used in a Phase I clinical trial as
on OV in patients with unresectable melanoma. In this
study the virus was found to be safe with only a few
low-grade side effects (fever, fatigue and mylagias)
reported. Vaccination resulted in the induction of anti-
viral antibody titers and generated gp100-specific T cell
responses that correlated with regression of injected le-
sions. We identified the immunoglobulin-like transcript
2 (ILT2) gene that was significantly down-regulated in T
cells exposed to the recombinant Vaccinia vectors using
a gene microarray strategy. ILT2 is a negative regulatory
protein that inhibits T cells responses and decreases
in ILT2 were associated with therapeutic responses in
vaccinated patients, suggesting this might be a useful
biomarker of clinical response.
An attenuated, recombinant herpes simplex type 1
virus (HSV-1) encoding GM-CSF has been constructed.
This vector has demonstrated regression of both injected
(oncolytic) and uninjected tumors in murine models.
HSV-1 encoding human GM-CSF was constructed and
has been named Talimogene Laherparepvec (T-VEC). T-
VEC was shown to be safe in a Phase I clinical trial and
was tested in 50 patients with locally advanced and
metastatic melanoma in a Phase II study [63]. This study
further demonstrated limited toxicity, induction of anti-
herpes viral titers in all patients and objective regression
of tumors in 28% of the treated patients, including
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patients also had biopsy specimens taken after vaccin-
ation which revealed the induction of a MART-1-specific
CD8+ T cell response and decreased numbers of CD4 +
FoxP3+ regulatory T cells, CD8 + FoxP3+ suppressor T
cells and MDSCc in injected lesions. Based on these data,
a large T-VEC has been tested in an international, multi-
institutional, randomized, controlled phase III clinical trial
with results expected in 2013.
In summary, understanding of the molecular drivers of
melanoma provides opportunities to target the disease in
a rational manner that may ultimately reduce the mor-
tality from the disease. Different signaling pathways have
been identified in melanoma with genomic analysis of
primary melanoma giving an insight into the molecular
drivers of the disease at an early stage in disease pro-
gression and include mutations in a variety of genes in-
cluding well established BRAF, NRAS, KIT, MAPK
kinases, and novel genes such RAC1. These genomic
changes frequently involve classic oncogenic pathways
including the PI3K/AKT/mTOR, RAS/RAF/MEK/ERK
and the CyclinD1/CDK4/pRB pathways. Mutations in
genes that activate these pathways provide opportunities
to therapeutically target the disease. Mutations in BRAF
in about 50% of melanomas can be inhibited by drugs
that target the RAS/RAF/MEK/ERK pathway including
vemurafenib, dabrafenib, and trametinib. Similarly, mu-
tations in NRAS in about 15-18% of melanomas also
activate the RAS/RAF/MEK/ERK pathway that can be
inhibited by MEK-inhibitors such as MEK 162. Other
therapeutic opportunities exist in targeting mutations in
ERBB4 present in about 10% of melanoma patients that
could be inhibited by lapatinib. Upregulated EphB4 re-
ceptor expression present in about 10% of melanomas
could be inhibited by nilotinib, and imatinib, sunitinib;
and nilotinib inhibit KIT mutations that occur in about
3-5% of melanomas.
BRAF inhibitors have dramatically changed the out-
come of patients with advanced disease that contain mu-
tations at the codon V600. However, the responses are
not long lasting and result in progressive disease in ma-
jority of patients. Significant progress has been made in
understanding the mechanisms of the intrinsic and ac-
quired resistance that can be both MEK-dependent and
MEK-independent. To overcome MEK-dependent resist-
ance the combination of a BRAF inhibitor (dabrafenib)
with a MEK inhibitor (trametinib), has resulted in sig-
nificant extension of PFS, when compared to dabrafenib
as single agent. BRIM 7 trial combining vemurafenib
with a potent inhibitor of MEK1/2 (GDC 0973 or
cobimetinib) demonstrated a high response rate in mel-
anoma patients’ naïve to BRAF inhibitors. However,
adding the MEK inhibitor to vemurafenib-progressive
patients, has led to a much less impressive response rate(< 25%). The well-documented immunotherapy approaches
for melanoma targeting key T cells immune check points
such as CTLA-4 and PD1-PD-L1 have already validated
the merits for combining these agents with targeted therapy
approaches. Targeted therapy increases the sensitivity of the
tumor for immunotherapy by recruiting immune cells into
melanoma lesions supporting the merit of combining those
two types of therapy to achieve clinical benefits. Other pos-
sible approaches to overcome developing resistance are to
target other aspects of melanoma biology downstream of
BRAF such as cell cycle regulation, tumor metabolism or
activation of an immune response. Potential therapeutic
strategies include the use of CDK4 inhibitors such as PD-
0332991, and inhibitors of glycolytic regulators of tumor
metabolism such as inhibitors of pyruvate dehydrogenase
kinase or lactate dehydrogenase that inhibit tumor cell glu-
cose metabolism. A cancer drug based on oncolytic virus
has also succeeded in a late stage clinical trial giving an-
other agent for multi-modality care.
In conclusion, many mechanisms of resistance have been
driving progression during anti-BRAF therapy, likely in-
volve MAP-kinase pathway in most cases, and it is likely
that more than one resistant mechanism is present at the
same time. It’s difficult, if not impossible, to target all the
resistance mechanisms after they have been “activated”, but
combination therapy used upfront may prevent resistance
(i.e., BRAFi plus MEKi). Combination therapy approaches
that incorporate targeted agents (e.g., vemurafenib) and
immunotherapy (e.g., ipilimumab, anti-PD1/PDL1) are
most promising and are already clinically explored. Des-
pite the remaining challenges, it is certain that rational
combination therapy for treatment of patients resistant to
BRAF inhibitors represents the future of metastatic mel-
anoma treatment.
Novel concepts
Melanoma is a complex and heterogeneous disease and
tumor may be composed of distinct cell populations
with distinct molecular features and varying response to
treatment. Inter-and intra-tumor heterogeneity within
primary tumours and between primary and metastatic
sites as well as developing resistance suggest the need
for novel approaches to identify predictive markers
closer to patients’ tumor allowing for rational design of
combination therapies instead of using a single biopsy
assumption. Additional challenge is how to use the
knowledge that cancer development and progression de-
pends on immune system and stroma and several areas
of new investigations provide promissing insights with
regard to development of successful treatments. Other
studies including the role of microbiota, mechanisms of
rejection and metastasis process are essential for con-
tinuous progress in the treatment of melanoma. Thus, it
is important that the agents to down-regulate the
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cial regulators of metastasis complimentary to targeting
tumor cells are considered for rational therapeutic
strategies.
Humans have co-evolved with microbial partners. We
are a composite of species: including bacteria, fungi and
viruses. In and on our bodies, microbial cells outnumber
the human cells by about 10 fold. In the intestine, the
total microbial DNA (the microbiome) may contain 100
times more genes than our ‘own’ human genome. The
microbiome is an integral part of our genetic landscape
and regulates metabolic functions. The development of
the immune system is even dependent on interactions
with the commensal microbiota.
Commensal bacteria affect local and systemic inflamma-
tion/immunity, influencing skin, mucosal and intestinal
immunity, and relative inflammation. In experimental
mouse model of subcutaneous transplanted tumor, antibi-
otics suppress the anti-tumor effect of anti-IL-10R/CpG
therapy, decrease inflammatory cytokine production in
the treated tumors, and suppress early necrosis of the
tumor. Antibiotics treatment also impairs the anti-tumor
effect of chemotherapy with platinum compounds such as
oxaliplatin [64].
Tissues respond to infection or damage with inflam-
mation and immunity in which all tissue cell types ac-
tively participate in order to fight infections, repair
damage, and restore tissue integrity and function.
Chronic inflammation can promote all phases of car-
cinogenesis, from initial genetic alterations promoting
tumor development, to establishing tumor environment
that promotes tumor initiation and progression, and
triggering immunosuppressive mechanisms that prevent
anti-tumor immune response. This intrinsic inflamma-
tion is carried out by epithelial cells, endothelial cells
(ECs), fibroblasts, infiltrating hematopoietic cells and
other stromal cells that produce cytokines, chemokines
and growth factors that affect tumor cells phenotype as
well as create micro-environment in surrounding tissues
which is responsible for activation of a proinflammatory
program. By contrast, extrinsic inflammation is activated
by the tissue response to the malignant cells, and it is
predominantly mediated by the infiltrating inflammatory
cells and regulates tissue rearrangement, angiogenesis
and ability of tumor cells to disseminate [65]. Oncogenes
such as RAS, BRAF, MYC, RET, Src affect not only
tumor cell proliferation and transformation but also pro-
duction of pro-inflammatory factors such as cytokines
and chemokines that activate inflammation by recruiting
inflammatory cells and creating environment with re-
duced anticancer response.
Involvement of different mechanisms and compounds
in inflammation is postulated. For example, the signaling
adaptor molecule myeloid differentiation factor 88(My88) downstream of most TLRs and of the IL-1 family
is central for the activation of NF-κB mediated innate in-
flammatory pathways. My88 is required for RAS induc-
tion of pro-inflammatory genes through a positive feed-
back mediated by IL-1α binding to the MyD88-coupled
IL-1R. An IL-1α autocrine loop in oncogenic RAS
transformed mouse keratinocytes is required for both
the secretion of pro-inflammatory mediators and, in
part, for the transformation phenotype [66].
Tumor-associated macrophages (TAM) are a key com-
ponent of cancer promoting inflammation [67-69] and
TAMs are generally skewed in an M2-like phenotype of
IL-12 and IL-23 low and IL-10 high with variable ca-
pacity to produce inflammatory cytokines [68]. Evidence
suggests that the inflammation driven by these cells pro-
motes tumor proliferation and progression, stimulates
angiogenesis and lymphangiogenesis, inhibits adaptive
antitumor immunity contribute to tissue remodeling and
promotes genetic instability. The potential of TAM
markers and, more in general, inflammation markers as
diagnostic tools to tailor chemotherapeutic and, most
important, immunotherapeutic approaches deserves
further study [70]. In particular, a distant relative of C
reactive protein, PTX3, has emerged as a potential cor-
relate of cancer related inflammation in diverse human
tumors [71]. The value of markers of inflammation as
predictors of response to immunotherapy in melanoma
is also of high importance. Strategies aimed at interfer-
ing with TAM recruitment yield encouraging results in-
cluding re-education with activation of the antitumor
activity of these cells [72] or reduction of their numbers.
There is evidence that TAM express high levels of PDL1
and therefore can be a target for PD1-PDL1 blocking
strategies. Approaches aimed at reducing the numbers
of TAM include inhibitors of chemokines and of colony
stimulating factor 1 (CSF-1). Recent evidence indicates
that trabectedin, an antitumor agent approved in Europe
for the treatment of sarcomas and ovarian carcinoma,
acts by depleting TAM in the mouse and in man [73].
These data provide proof of principle evidence that
targeting TAM offer promise for the development of ef-
fective therapeutic strategies.
Ulcerated melanoma is a distinct biologic entity, con-
sidering that survival is much lower for same Breslow
thin melanomas [74]. Ulcerated melanomas differ from
non-ulcerated melanomas in terms of stromal response
[75] gene profile signature [76] and a sentinel node im-
mune-suppression status [77]. Analysis of the data from
two large phase III trial with IFN as adjuvant therapy for
melanoma, the EORTC 18952 (intermediate doses of
IFN-α2b) and the 18991 pegylated-IFN (pIFN), demon-
strated that ulceration is predictive for the efficacy of ad-
juvant IFN/pIFN therapy. In both of these trials patients
with ulcerated melanoma have an advantage in relapse
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(DMFS) and in OS according to the stage (IIb & III –
N1) versus the non ulcerated melanoma patients
[78-80]. This advantage disappears in N2 patients. The
EORTC Study 18991, after a 7.6 years follow up, con-
firmed the data of advantage in this subgroup of pa-
tients, by a 42% Relative Risk reduction in overall
survival [81]. Also in the SUNBELT trial only patients
with ulcerated melanoma benefitted from IFN treatment
[82]. Even from the Wheatley meta-analysis of IFN as
adjuvant therapy in melanoma, ulceration emerged as
the advantage for melanoma patients, so that ulcerated
melanoma can be considered a distinct biologic entity
because only ulcerated melanoma is sensitive to IFN,
while non ulcerated melanomas seem to not benefit at all
from adjuvant IFN therapy [11]. The EORTC 18081 trial
in ulcerated stage II melanoma patients evaluates pro-
spectively the benefit of adjuvant pIFN in this setting.
Intratumour heterogeneity (ITH) is variability within a
tumour. Clinicians, particularly pathologists, have under-
stood morphological differences in cancer for decades.
ITH includes variability within primary tumours and be-
tween primary and metastatic sites
In the same patient. ITH can be viewed in an evolu-
tionary framework and has been identified clearly in
renal cell carcinoma (RCC). A fundamental question for
personalised medicine is whether the putative driver
identified from tissue “x” at time “y” really does drive the
metastatic disease in the patient in the clinic. Further-
more, do image-guided biopsies of large renal tumours
represent the entire primary, never mind the burden of
metastatic disease? Single biopsy assumptions are that
the tumour somatic/transcriptomic landscape is repre-
sented and provides robust prognostic and predictive
biomarkers of outcome and that mutations are ubiqui-
tously present in every region of a tumour and can be
used for sequencing analysis to stratify patients for
therapeutic trials. But these assumptions are not always
valid. The E-PREDICT study [83] compared mutations
between primary RCC tumours and metastases, showing
that 65% mutations are heterogeneous and are not
present in every biopsy in the patients reported.
There may be evidence for ITH in melanoma;
polyclonality of BRAF mutations in primary and metastatic
samples has been shown and in samples from patients re-
sistant to Vemurafenib, persistence of BRAF mutations
has been shown. These melanomas, however, have ac-
quired NRAS mutations or PDGFRβ overexpression. Fur-
thermore, distinct subclones identified with IHC within a
metastasis progressing on vemurafenib have been studied:
one remained BRAF mutant; the other acquired NRAS
mutation in addition. Re-sensitisation of patients to BRAFi
therapy after time off treatment is another interesting ob-
servation that may be explained by ITH [84].Concluding, intratumour heterogeneity has been
around for decades, and in RCC, as in other cancers, it
can be demonstrated using multiple methods. Evidence
for ITH in melanoma is perhaps less convincing at
present, but it is plausible though that it may be relevant
to drug resistance. Further study is needed (e.g. detailed
longitudinal tissue collection), to investigate if ITH may
impact on therapeutic strategies.
Stereotactic radiotherapy (SRT) can be considered the
best local treatment for brain metastases, controlling
nearly all treated lesions for at least several months.
Since the advent of SRT over a decade ago, the pattern
of survival has changed to longer and more likely to suc-
cumb to extracranial disease than to brain metastases.
Melanoma brain metastases have always been considered
a “death sentence” with less than 6 months’ median sur-
vival for most subgroups of patients. Fortunately, ques-
tions about the risks and biology of brain metastases
(e.g., molecular pathogenesis, tumor-host relationships,
site of primary and its environmental and genetic fea-
tures) have started to see answers, and much new infor-
mation is expected from collaborative networks that
have been developed to answer these and other ques-
tions about biology and management of brain metasta-
ses. In 296 patients with resected brain met(s) BRAF and
NRAS status was determined, and they were evaluated
between Jan 2005-Dec 2011 (before BRAFi, MEKi ther-
apies) [85]. In terms of difference in median age, BRAF
wild-type (WT) patients were 66 years, while BRAF
(all comers) and NRAS mutated patients were mid-50s.
Of 99 pts (33%) with symptomatic brain metastases, 13
(17%) were WT Type, 21 (40%) were NRAS mutated
and 65 (39%) were BRAF mutated. The outcome of the
patients with melanoma brain metastases resulted diffe-
rent according to the mutational status. Wild-type
patients had a better prognosis compared to mutated pa-
tients (any mutation/WT HR 1.88, p = 0.04), and the pair
wise comparison evidenced a better prognosis for
BRAF-mutated patients than NRAS-mutated pts (BRAF/
WT HR: 1.75; NRAS/WT HR: 2.31). The subgroup ana-
lysis showed that the differences in outcome among the
three groups of patients could be lessened by locally ab-
lative treatments, although there was a persistent advan-
tage for WT pts. Recent single-patient case reports have
been informative and led to formal testing in Phase II
trials. Thus, a report by Rochet et al. showed a patient
with a BRAF-mutated melanoma who failed to benefit
from ipilimumab but experienced a response of brain
metastasis to vemurafenib [86]. At the 2010 ASCO Con-
gress the preliminary data on dabrafenib, another BRAF
inhibitor similar to vemurafenib, in the treatment of
melanoma patients with brain metastases were presented
[4]. Of 10 treated patients, there were 3 CR, 5 PR, 1 MR
and 1 SD, for an 80% BORR (best objective response
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[“BRAF E and K” mutations]-MB [Melanoma Brain]
trial, enrolling melanoma patients with brain metastasis,
harboring V600 mutation, previously treated or un-
treated with radiotherapy, to be treated with dabrafenib.
For patients untreated with radiotherapy, brain OR was
39% (E600E), and 7% (V600K), while for previously
treated brain OR was 31% (V600E) and 22% (V600K).
Ipilimumab was tested in two clinical trials to identify
safety and overall survival of patients with advanced
melanoma and brain metastases. Dose/schedule were
identical at 10 mg/kg q 3 wks × 4, followed by 10 mg/kg
q 12 weeks until relapse or intolerance. The two trials
are the CA184-042 trial and the CA184-045, an open-
label, expanded-access treatment protocol. Patients who
qualified for these trials experienced an approximately
20%-25% durable benefit at 2+ years of follow-up, with
rare progressions beyond this time.
The NIBIT trial, associating ipilimumab at the dosage
of 10 mg/kg with fotemustine, treated melanoma pa-
tients with brain metastases. Results were 40% overall
disease control rate, and 50% CNS disease control rate,
with a good toxicity profile. The role of fotemustine is
unknown and is being studied in an ongoing randomized
trial but the drug is unavailable in the U.S. Although
ipilimumab has been combined with cytotoxic agents
such as dacarbazine and temozolomide (TMZ), the ben-
efits of each component and their interactions could not
be assessed from the trial designs. Toxicities may limit
the further exploration of such combinations, and there
is currently greater enthusiasm for combinations of
checkpoint blockade with molecularly targeted agents.
Nevertheless, some of the current immunotherapeutic
strategies are investigating the use of selected chemo-
therapies to transiently lymphodeplete the patient in an
effort to alter T cell subsets and stimulate them with in-
creased levels of homeostatic cytokines.
Brain vascular endothelium promotes metastatic
growth, invasion, altered architecture and function.
Fewer vessels are more permeable and viable or hypoxic
tumors produce VEGF by hypoxia-related gene expres-
sion, and tumor-associated stromal cells, e.g., fibroblasts,
contribute to support metastases. Microglia and astro-
cytes may also be protective. Blood–brain barrier (BBB)
histologically is composed of ECs, pericytes, astrocytic
perivascular endfeet and makes an active process of
blocking, because molecules can’t pass through tight
junctions, but must pass through cells. An active trans-
port system regulates the passage of small hydrophilic
molecules, while large hydrophilic molecules are ex-
cluded or admitted via receptor-mediated endocytosis
[87]. The barrier breaks down in tumors over 1–2 mm,
and heterogeneity of BBB within/around tumors may
protect tumor against effective radiotherapy. Varioustherapeutic strategies have been directed to overcome
tumor-protective BBB as Lipoprotein-related protein-1
targeting of cytotoxic agents, inhibitors of drug-efflux
pumps/multi-drug resistance and use of drugs that cross
intact BBB, e.g., fotemustine, TMZ, and anti-angiogenic
therapies that include Abs and small molecules.
Molecular mechanisms are common to various malig-
nancies. Between these the most important are VEGF,
hypoxia-related genes, WNT signaling, EGFR-related,
Immune/inflammatory (TGF-β expression, CD4, NK
cells, B7-H3).
Molecular mechanisms of particular interest for mel-
anoma are STAT3 that regulates angiogenesis gene ex-
pression VEGF, and results in improved brain
metastases with respect to primary tumor, so the level of
gene expression are associated with potential for brain
metastasis. Rx synergy of STAT3 block, and AKT that is
hyperactivated in human brain metastases without
PTEN loss promoted brain metastasis was modeled in
genetically-engineered mouse. AKT may be activated by
secreted product of astrocytes, and can have therapeutic
implications [88].
Nab-paclitaxel is the first nanotechnology-derived
agent approved for the treatment of breast cancer. This
formulation exhibits linear pharmacokinetics over a clin-
ically relevant dose range 3, which means predictable
drug exposure with dose modification. Compared with
solvent-based paclitaxel, nab-paclitaxel exhibits linear
pharmacokinetics, ~10-fold increase in Cmax and ~3-fold
higher AUC (area under the curve) of unbound paclitaxel,
potential binding to albumin-binding proteins and shows
enhanced transport across endothelial cell monolayers,
with a 33% higher paclitaxel concentration in tumor xeno-
grafts [89].
Melanoma cells express high levels of SPARC (serum
protein acidic and rich in cysteine), an albumin-binding
protein that may facilitate delivery of nab-paclitaxel to
tumor cells. SPARC, also known as Osteonectin and
BM-40, is a 43-kDa glycoprotein that interacts with
extracellular matrix proteins. Normal functions of
SPARC may include tissue remodeling, angiogenesis, cell
motility, mineralization of bone and cartilage, and em-
bryonic development. SPARC is overexpressed in many
cancers, especially in cells associated with the tumor
stroma and vasculature, and it may play a role in tumor
progression in different cancer types.
There is a direct correlation of SPARC expression and
OS in patients with pancreatic cancer who received nab-
paclitaxel plus gemcitabine, as evidenced in a Phase I/II
Trial, with a median OS of 17.8 months in the high
SPARC expression group vs. 8.1 months of low SPARC
expression group. Although high SPARC expression is
typically a poor prognostic factor, it actually predicted
an improved response to nab-paclitaxel in terms of OS.
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promising efficacy, differently from cremophor-paclitaxel
or docosahexaenoic acid-paclitaxel, that produced lim-
ited clinical benefit. The phase III trial randomized 514
pts with chemo-naïve metastatic cutaneous melanoma
to be treated with nab-paclitaxel or dacarbazine. Primary
efficacy endpoint was PFS while secondary efficacy end-
points were OS, ORR and DCR. PFS of nab-paclitaxel
group resulted 4.8 months, while PFS of dacarbazine
group resulted 2.5 months. The advantage was also
obtained in OS with 12.8 months for nab-paclitaxel
group vs. 10.7 months for dacarbazine group. The BRAF-
mutational status did not change the outcome of nab-pac-
litaxel group. Improvement in PFS with nab-paclitaxel
occurred in all patients regardless of age (<65, ≥65 years),
region, BRAF mutation status, and baseline LDH (lactate
dehydrogenase) level. In particular, for patients with the
most advanced melanoma (M1c), nab-paclitaxel produced
significantly longer PFS (HR: 0.734; 95% CI: 0.558–0.965,
P = 0.028) compared with dacarbazine. The treatment
showed a good safety profile [90].
Nab-paclitaxel is the first taxane and first single-agent
chemotherapy in 35 years that demonstrated superiority
compared with dacarbazine with a near doubling of me-
dian PFS, a 44% improvement in disease control rate
(DCR), and a trend towards OS benefit in chemo-naïve
patients with metastatic melanoma. Future perspectives
could consist in the combination of nab-paclitaxel with
newly approved biologic/immunologic therapies (BRAF
inhibitors in BRAF mutated patients or ipilimumab
independently of BRAF mutational status).
Understanding how tumor rejection occurs under a
given immunotherapy is one of the primary goals of clin-
ical research in order to optimize existing immunotherapy
and development of new therapies. Through multiple can-
cer immunotherapy molecular monitoring, a repetitive
phenomenon has been observed that the activation of dif-
ferent factors as STAT1/IRF1, allograft inflammatory fac-
tor 1, IL-15, IL-6, Granzyme A, B, K, Perforin, CCL4
(MIP-1b), CXCL10/IP-10, CXCL9/Mig, and/or CCL5
are necessary for tumor rejection. Nevertheless, tumor
rejection is a multifactorial process involving host’s gen-
etic background, environmental/hidden factors and
tumor genetics.
In order to dissect contribution of each components
to the clinical outcome of melanoma patients undergo-
ing adoptive T cell therapy TILs from 142 patients en-
rolled in adoptive T cell therapy trials, 112 parental
melanoma metastases and 15 melanoma cell lines de-
rived from melanoma metastases were analyzed. Global
transcriptome analysis of the tumors sample using gene
expression array analysis, micro RNA profiling as well as
genome wide single nucleotide polymorphism (SNP) as-
sociation analysis of advanced melanoma patients whoachieved CR and of those that progressed (NR) was
performed. The results demonstrate that TILs that lead
to complete tumor regression in patients share a gene
signature distinctive of memory cells. Pathway enrich-
ment analysis revealed down regulation of genes as-
sociated with differentiation as well as enhanced
proliferation function in CR compared to NR patients.
The data underscore the notion that these T cells are less
differentiated but have enhanced proliferative phenotype
consistent with recently published data [91]. These
memory T cells which were designated memory stem T
cells (TSCM cells) share the similarity of naïve phenotype
comparing with effector T cells that have more prolifera-
tive properties and prolonged survival post adoptive
transfer in preclinical model.
Significant segregation of responders from non-re-
sponders was also observed based on the gene expres-
sion profile of the tumor cell lines, leading to the
conclusion that immune responsiveness is at least in
part dependent upon the biology of cancer cells [92].
Comparison of the miR profile in complete responders
versus nonresponders identified 13 distinct miRs be-
tween CR and NR, suggesting that clinical outcome can
be regulated at the epigenetic level. Genome-wide scan
analysis of germline SNPs based on allele frequency
identified 5 loci in IRF5 gene with global significance
that were associated with clinical outcome suggesting
that genetic polymorphism is an important component
determining tumor rejection.
Concluding, immune responsiveness is at least in part is
dependent upon the genetic background of the host and
the biology of cancer cells. The finding that adoptive T
cells have enhanced proliferative capacity and can sustain
the function of memory and effector T cell subsets has
considerable implications for the design of T cell–based
therapy to target intracellular pathogens and cancer.
Sentinel node biopsy has completely changed the sur-
gical approach to melanoma patients, it has permitted to
stage properly the patients and it has opened new ways
of researches on the biology of tumor metastases. By the
newer technologies a computer-assisted probe with ad-
justable collimation has been developed. By this ma-
chine, energy windows can be calibrated by computer,
according to the energy spectrum emerging from each
patient. In this way, the possibility to optimize photo-
electric/compton efficiency reduces the dimensions of
the smallest detectable node, possibly reducing the false
negative sentinel lymph node biopsies and the possibility
of errors of surgeons and nuclear radiologists. Conven-
tional SPECT imaging is a Single Photon Emission Com-
puted Tomography [93]. The Free Hand SPECT is a real
extension of gamma probe for 3D imaging that could be
easily positioned in the operative room. By the elabor-
ation of the computer, Free Hand SPECT gives real-time
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acustic signal. By preliminary tests, this device seems
useful in cases of SN near the melanoma, deep nodes,
over-weight patients and to confirm that no hot nodes
remains in site at the end of the procedure.
Sentinel node (SN) is the first point of contact be-
tween tumor-associated antigens and the adaptive im-
mune system, and is the site where dendritic cells (DCs),
the professional antigen presenting cells (APCs), are
expected to present tumor antigens to naive T-cells gen-
erating specific responses against tumors. SNs show
down-regulation of APCs, because DCs show little or no
formation of dendritic processes. Plasmacytoid dendritic
cells (p-DCs) have been described in primary melanoma
lesions and p-DCs represent the main source of IFN-α.
There is a possible role of p-DCs in priming naive mel-
anoma-specific CD8+ T-cells as well as in IFN produc-
tion. The infiltration of p-DCs has a prognostic value in
primary breast cancer, as its presence correlates with ad-
verse outcome. p-DCs are rarely detected in lymph
nodes of healthy subjects. p-DCs have been demon-
strated in SN of melanoma patients and they accumulate
around melanoma nests in situ, and their percentage in-
creases in presence of melanoma metastasis [94].
Langherans Cells (LCs) represent the major DCs subset
in melanoma SN; they have low expression of CD83,
CD80, CD86, HLA-DR markers, and CD83 positive LCs
are lower in SN positive than in SN negative melanoma
patients [95]. These data could support the hypothesis of
new therapeutically effective strategies, in order to re-
verse the immune suppression of tumor related nodes,
possibly inducing an effective immune response against
the tumor.
Electrochemotherapy (ECT) is a new therapy for cuta-
neous metastases that uses reduced doses of antineo-
plastic drug in association with electroporation to create
a difference of potential in the cell membranes that
opens the pores by which the chemotherapy agent enters
inside the cell and gives a cytotoxicity-induced DNA
break. Electrochemotherapy is effective, with 85% Ob-
jective Response (OR), 73.7% CR and 11.1% Partial Re-
sponse (PR). The procedure is safe; the side effects are
absolutely slights with only erythema, edema, necrosis,
discromia and with no grade III-IV toxicity. Possible
mechanisms of action are cytotoxicity on cancer cells
that give necrosis and apoptosis of cancer cells by elec-
tric pulses. Immunological mechanisms could play a
role, as 80% of tumors cures were achieved in immuno-
competent mice and none in immunodeficient mice.
Moreover, it has been demonstrated a reduction of epi-
dermal LCs at biopsies performed at day 7 post-ECT, an
increase of epidermal LCs at day 14 post-ECT, an in-
creased amount of peri-tumoral dermal DCs CD1c+,
HLA-Dr + post-ECT and the appearance of peri-tumoralCD83+ DCs in the dermis post-ECT [96]. All together
these data indicate that ECT could induce migration and
activation of LCs. It could be hypothesized that ECT
triggers initial and local immune responses in treated le-
sions and it could also be hypothesized to modulate this
scenario and enhance the potential ECT actions [97].
According to these immunological stimulations, a trial
of ECT plus ipilimumab has been planned.
Liver metastases are a typical manifestation of progres-
sion of disease of uveal melanoma, but even cutaneous
melanoma demonstrates predominant hepatic metasta-
ses in some cases. Liver anatomy is favorable to vascular
isolation, as tumors receive the majority of their blood
flow from the hepatic artery, and hepatic metastases are
often the cause of death of the patient. Isolation and ar-
terial perfusion of the liver eliminates or significantly re-
duces systemic toxicity, and allows higher doses of toxic
chemotherapy. Isolated liver perfusion began in the
1960’s, using an open, operative technique. The advent
of advanced vascular catheters and an extracorporeal
venous hemofiltration system have allowed development
of a minimally invasive, percutaneous technique. A
phase I study of Hepatic Arterial melphalan Infusion
and Hepatic Venous Hemofiltration using percutaneous
catheters in patients with unresectable hepatic malignan-
cies enrolled 12 patients treated at dose of 2.0 mg/kg
then dose escalation (2.5, 3.0, 3.5 mg/kg) [98]. Planned
treatment course included 4 treatments separated by
4 weeks, and 3 mg/kg was the maximum tolerated dose.
Dose limiting toxicities were neutropenia and throm-
bocytopenia. Overall radiographic response rate was
30%. Among the 10 patients with ocular melanoma, a
50% overall response rate was observed, including two
complete responses. With chemosaturation therapy
using percutaneous hepatic perfusion (CS-PHP) it is
possible to use dosages of melphalan 12 times higher
than the dose used for the systemic treatment of mul-
tiple myeloma. At the 2010 ASCO Congress phase III
data were presented, in which 93 pts with Stage IV mel-
anoma - Liver-only/liver predominant metastases (strati-
fied as cutaneous or uveal) were randomized to receive
CS-PHP or best alternative care. Significant improve-
ment in the primary endpoint was obtained with an
extension of median PFS by 6.6 months (HR 0.30
(p < 0.0001). There was consistent improvement in sec-
ondary endpoints, but the crossover design of the trial
precluded evaluation of an impact on OS [99]. Expected
bone marrow toxicities of melphalan were the main side
effect. New developments for CS-PHP include second
generation filters, with improved drug extraction effi-
ciency. First generation filters have a clinical extraction
efficiency of 77%, whereas in bench-top experiments,
second generation filters have extraction of approxi-
mately 97%. Demonstration of improved extraction and
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are pending in ongoing studies.
Bridge between melanoma and colo-rectal cancer:
biology of tumor microenvironment
Discovery of specific mutations leads to development of
clinically useful inhibitors of critical signaling pathways
but usually is limited to specific type of tumor. However,
the importance of the immune response and the role of
microenvironment in cancer development, progression
and metastasis has been recognized as potential therapy
target to improve cancer patients survival in many
tumor types, including melanoma. For example, the cri-
tical role of the microenvironment in the growth of can-
cer is supported by the role and the therapeutic
potential of angiogenesis. Current data indicate that se-
creted stromal factors that can mediate drug resistance
and predict response to treatment based on microenvi-
ronmental factors could be shared between various tu-
mors. Thus, promising studies of microenvironment and
immune response in different type of tumors can benefit
melanoma and vice versa as discussed in this section.
A lack of balance of host tumor interaction is due to
numerous interactions and is mediated by at least three
distinct escape mechanisms involving:1) alteration of
genomic and phenotypic features of tumor cells them-
selves (expression of tumor antigens, somatic mutations,
up-regulation of anti-apopototic molecules, 2) the tumor
micromilieu (melanoma cells interact with the micro-
environment in bidirectional manner through molecular
signals that modulate malignant phenotype), as well as
3) immune cells that can either become immunosup-
pressed or reject the tumor cells. Cancer cells interact
with stromal cells by production of certain factors affec-
ting fibroblasts or ECs resulting in a cascade of events
leading to progression For example, melanoma cells se-
crete growth factors such as FGF-β PDGF, and TGF-β
that affect angiogenesis and stroma formation by indu-
cing proliferation of fibroblasts and ECs. The melanoma
cells can also produce VEGF resulting in ECs growth. In
return, EC produce chemokines resulting in melanoma
cell migration (e.g., CCR4) via receptors found on melan-
oma cells that can contribute to drug resistance to cancer
therapy. HGF secretion by stromal cells was shown to be
responsible for resistance to targeted therapy including
BRAFi. The impact of interactions of tumor cells and
stroma is increasingly recognized as important target to
individualize therapy for melanoma patients.
An altered interplay between immune system and
tumor cells towards inflammation that promotes car-
cinogenesis represents a major cause of tumor progres-
sion. This process includes downregulation of MHC
molecules, secretion of immune suppressive cytokines
(VEGF, IL-10 and TGF-β, recruitment of inhibitoryimmune cells (e.g., Treg and MDSCs) and others. Loss
or downregulation of HLA class I antigens often occurs
in tumor cells and is associated with disease progression,
reduced survival of patients as well as lack of response
to T cell-based immunotherapies. Although, metastasis
expressing HLA class I antigens in melanoma patients
undergoing immunotherapy can regress immunother-
apies can partially generate HLA class I loss variants
causing progression. The HLA class I abnormalities are
mediated by an impaired expression and functional de-
fect of distinct components of the antigen processing
machinery (APM) resulting in a decreased HLA class I
surface expression, an altered antigen repertoire as well
as a reduced recognition by CD8+ cytotoxic T lympho-
cytes (CTL) [100]. The molecular mechanisms of defect-
ive APM components expression may include structural
alterations in β2-microglobulin, the MHC class I heavy
chain (HC) as well as the peptide transporter TAP, but
these are rare events in melanoma. In most cases, de-
regulation of the APM components that are found, oc-
curs at the transcriptional or post-transcriptional level
or they it is regulated by epigenetic mechanism. These
data suggest that the deregulation of HLA class I APM
components is a major cause of deficient HLA class I
surface expression in melanoma. The challenge in the
future is the identification of regulators of APM com-
ponents, which are able to specifically modulate their
expression. Furthermore, in addition to aberrant expres-
sion of classical HLA class I antigens, the non-classical
HLA-G is often discordantly expressed in renal cell car-
cinoma and melanoma [101]. HLA-G expression caused
a reduced sensitivity of NK- and T cell-mediated cyto-
toxicity. We have recently identified HLA-G-specific
microRNAs, which might serve as a tool for prognosis
and therapy selection due to an inverse expression be-
tween HLA-G and microRNA expression, which appear
also to correlate with disease progression.
Targeting antigens expressed by tumors in their micro-
environment was evaluated in a multi-step process that
focused on patients with non small cell lung cancer
(NSCLC) or prostate cancer who received autologous
tumor vaccines. Protein arrays (ProtoArray) were used to
detect the difference in pre- and post-treatment antibody
responses. Since autologous tumor was not available for
most patients, gene expression profiles of established cell
lines were used. Studies with NSCLC patients exhibiting a
CR (n = 3) or stable disease (n = 1) found a common pat-
tern of antibody responses against antigens that were
shared by the 13 NSCLC cell lines [102]. Next IHC ana-
lysis of normal and lung cancer tissue specimens from tis-
sue arrays were evaluated for expression of the proteins
identified as targets of a post vaccine antibody response.
For a panel of three antigens studied, malignant tissue, but
not normal tissue, stained strongly positive for expression
Ascierto et al. Journal of Translational Medicine 2013, 11:137 Page 23 of 29
http://www.translational-medicine.com/content/11/1/137of markers tested. These data argue that the ProtoArray
technology can be used to assess antibody responses
against targets relevant to cancer immunotherapy.
Next a novel immunotherapy strategy employing
autophagosome vaccines that contain defective ribosomal
products (DRiPs) and short-lived proteins (SLiPs) was
reviewed. DRiPs and SLiPs are the center of MHC class I
antigen processing pathway, and link the immunosur-
veillance of viruses and tumors. DRiPs enable the immune
system to rapidly detect alterations in cellular gene expres-
sion with great sensitivity. DRiPS and SLiPS are rapidly
degraded by proteasome, transported to the endoplasmic
reticulum, bound by MHC Class I and transferred to the
cell surface where they are postulated to contribute the
majority of peptides decorating the surface of tumor cells.
Proteosome blockade shunts DRiPS and SLiPS to the au-
tophagy pathway and by blocking a degradative step,
autophagosomes can be harvested and used as a vaccine.
In preclinical studies, an autophagosome vaccine was
more therapeutic than a “Gold Standard” GVAX Vaccine
in a 3 day-established 3LL tumor model. Additional stud-
ies documented that autophagosomes from one unique
sarcoma can prime an immune responses against other in-
dependently-derived syngeneic sarcomas and can provide
a significant level of protective immunity (challenged
14 days post vaccination) in 8 of 9 tumor combinations
tested. In contrast, whole tumor cell vaccines only pro-
vided protection from a tumor challenge when the chal-
lenge was identical to the tumor used as a vaccine [103].
These findings broke a paradigm with chemically-induced
sarcomas that had stood for more than 50 years. As such
we consider it to be a promising strategy to move into pa-
tients. Thus, an Autophagosome Cancer Vaccine derived
from two human cancer cell lines, one of mixed squa-
mous/adenocarcinoma and another adenocarcinoma, was
developed. This vaccine contains at least six of the tumor
antigens prioritized by NCI, agonists for TLR 2, 3, 4, 7
and 9 as well as HSPs. An NCI-funded randomized multi-
center phase II trial of cyclophosphamide with allogeneic
non-small cell lung cancer (NSCLC) DRibble vaccine alone
or with Granulocyte-Macrophage Colony-Stimulating
Factor (GMCSF) or Imiquimod for Adjuvant Treatment of
Definitively-Treated Stage IIIA or IIIB NSCLC will start in
early 2013. A similar phase II DRibble vaccine trial in
breast cancer will start later in 2013.
For optimal therapeutic vaccination against cancer
concentrated antigen delivery (DNA, RNA, SLP) with
appropriate adjuvant is crucial. Synthetic vaccines allow
rational vaccine design. Favoured cancer target antigens
are involved in cancer initiation, progression and/or me-
tastasis. Example: oncogenic proteins E6 and E7 of high
risk HPV. Long peptide vaccines harboring both CD4
and CD8 T cell epitopes and requiring DC processing
are efficient and were found capable of causing >50CRor PR in patients with high grade vulvar intraepithelial
neoplasia (VIN), caused by HPV16 [104,105]. DNA
prime/long peptide boost may be considered. Processing
route of SLP appears to differ from that of proteins. Fur-
ther improvements are seen by adding pegylated type I
Interferon or TLR ligands but especially by conjugating
TLR ligands to the long peptides. For maximally ef-
fective cancer treatment combination treatment such as
long peptide vaccination with chemotherapy or irradi-
ation and inhibitors of checkpoint control monoclonal
antibodies (CTLA-4 blocker, PD-1, PD-L1 blockers,
anti-IL6 (R), anti-IL10 (R), anti-TGF-β (R) and other im-
munomodulators) could be applied. Reduce toxicity of
the monoclonal antibody treatments by local delivery in
slow release formulation close to tumor-draining lymph
nodes is observed. Adoptive transfer of cancer-specific
T cells is best combined with optimal vaccination.
Malignant Mesothelioma (MMS) is a rapidly progres-
sive lethal tumor and the incidence is steadily increasing
worldwide. An actual “epidemic” is expected over the
next 10–15 years. No standard treatment significantly
improves prognosis of MMS patients. Median OS is
12 months (ranged from 6 to 18 months) from diagno-
sis. Survival in pretreated patients is even poorer. The
second-line therapy is undefined and enrollment in clin-
ical trial for fit patients is encouraged. Immune therapy
can be considered a good option of treatment, consider-
ing evidence demonstrating that lymphocytic infiltration
of pleural mesothelioma correlated with a better survival.
Consistently, it has been observed that patients with high
level of tumor infiltrating T cells have an overall survival
much longer than the patients with a low rate. Along this
line different immunotherapeutic agents have been tested
in MMS patients but with disappointing results. Anti-
CTLA-4 mAb potentiate the anti-tumor immune re-
sponse. The anti-CTLA4 mAb ipilimumab significantly
improves the survival of metastatic melanoma patients
(20% long-survivors to 4-yrs) and it is currently in clinical
development for other indications. The anti-CTLA-4
mAb tremelimumab has been extensively tested in differ-
ent tumor types, and it is currently being investigated for
different indications. Both ipilimumab and tremelimumab
can induce durable stabilization and clinical response
(even after initial disease progression).
The MESOT-TREM-2008 Study is a second line, sin-
gle arm, phase II study with the anti-CTLA-4 mAb
tremelimumab in chemotherapy-resistant advanced ma-
lignant mesothelioma [106]. The aim of the study was to
investigate safety, tolerability, clinical and immunologic
activity of the drug in this cancer. Primary end-point
was objective response rate, and secondary end-points
were safety, disease control rate (CR + PR + SD), PFS,
OS, and immunologic activity. From May 2009 to Janu-
ary 2012, 29 advanced MMS patients were enrolled.
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MMS patients, and can induce durable stabilization of
disease, warranting further investigation. The AEs ob-
served in this study are consistent with tremelimumab
safety profile in other indications and treatment associates
with major changes in T cell subpopulations. In light of
these encouraging results, the Study MESOT-TREM2012
is currently ongoing to explore a different schedule of
treatment with tremelimumab in refractory MMS
patients.
Melanoma comprises multiple clinical forms that arise
and develop through different pathogenic pathways, and
understanding pathophysiological implications of spe-
cific genes associated with metastatic lesions is crucial to
identify new prognostic and therapeutic targets. Consist-
ent with the contribution of VEGF and integrin VLA-4
to prometastatic effects of IL-18 in experimental melan-
oma models [107], we studied genes associated to mel-
anoma cells’ ability to form metastasis under IL-18
effects, and analyzed their expression in primary and
metastatic lesions from melanoma patients. We verified
that human melanoma cell lines with IL-18R/VEGF/
VLA-4 phenotype produced a higher metastasis number
in nude mice than those melanoma cell lines not using
this prometastatic pathway. Moreover, distinct signature
genes for melanoma cell lines with and without IL-18R/
VEGF/VLA-4 phenotype were also identified under basal
and IL-18 treatment conditions, through a genome-wide
transcriptional comparison. Next, we performed a hier-
archical cluster analysis of transcript patterns from a col-
lection of metastatic lesions from advanced stage
melanoma patients. Interestingly, all the studied melan-
oma metastases expressed signature genes from un-
treated melanoma cell lines irrespective of their IL-18R/
VEGF/VLA-4 phenotype. However, only cutaneous me-
tastases and a third of lymph node metastases expressed
signature genes from the specific transcriptional re-
sponse to IL-18 of melanoma cell lines with, but not
without IL-18R/VEGF/VLA-4 phenotype. Furthermore,
most of studied cutaneous primary melanoma lesions
also expressed signature genes from IL-18-treated mel-
anoma cell lines with IL-18R/VEGF/VLA-4 phenotype,
irrespective of their Breslow indices, suggesting that IL-
18R/VEGF/VLA-4 phenotype is already operating at
early stage melanomas.
Results of this study demonstrated the occurrence of
metastatic lesions with and without IL-18-dependent
genes, suggesting that human melanoma metastasis devel-
opment occurred via inflammation dependent and inde-
pendent mechanisms. Signature genes from melanoma
cell lines with and without IL-18R/VEGF/VLA-4 pheno-
type may serve as functional biomarkers of melanoma
predisposition to prometastatic effects of IL-18. In this re-
gard, melanoma lesions overexpressing those specificgenes from untreated (TGFBI, FEZ1, SLC20A1, POLM,
GPKOW) and IL-18-treated (UBE2C, UMPS, IQCE,
PFAS, PPAT, PTPLAD, ZBTB9) highly IL-18R/VEGF/
VLA-4-expressing melanomas, may be susceptible to
prometastatic effects of IL-18, and therefore, should not
be treated with this cytokine and other immunotherapies
increasing inflammation. Conversely, those genes from
highly (CD52, PRSS23, TMEM42) and low (CAPN3,
A2M, ARID4A, CNOT6L, CYB561) IL-18R/VEGF/VLA-4
expressing melanomas not expressing IL-18-dependent
genes, may be helpful to detect IL-18-unresponsive mel-
anoma lesions, and therefore, better candidates for im-
munotherapy [108,109].
Reported signature genes allowed for first time the clas-
sification of metastatic melanoma lesions according to
IL-18R/VEGF/VLA-4 phenotype and IL-18-dependent
gene expression. These genes may have diagnostic value
as pathogenic biomarkers and therapeutic targets of mel-
anoma predisposition to prometastatic effects of IL-18. At
present, it is unknown if IL-18R/VEGF/VLA4 phenotype
is necessary and sufficient for the determinism of metasta-
sis in melanoma patients. However, many of the genes as-
sociated to IL-18R/VEGF/VLA4 phenotype are candidates
for involvement in pathogenic mechanisms of melanoma
metastasis based on their known function in melanoma
and other malignancies. Therefore, these genes may also
be a source of potential targets for the specific treatment
of metastases developed via IL-18-dependent and inde-
pendent mechanisms.
Traditionally, the anatomic extent of the tumor burden
in colorectal cancer (CRC) and other type of solid tumors
has been the most important prognostic factor. Data on
the tumor burden (T-stage), combined with the presence
of cancer cells in draining and regional lymph nodes
(N-stage) and evidence of metastases (M-stage), amalgam-
ate to provide tumor staging (AJCC/UICC-TNM classifi-
cation). TNM stages estimate patient post-operative
outcome and the rationale for adjuvant therapy. Despite
the prognostic power of this staging system, it is becoming
recognized within the cancer community that clinical out-
come can significantly vary among patients within the
same stage. The current classification provides limited
prognostic information, and does not predict response to
therapy. Advances in this field have alluded to the import-
ance of the immune prevalence within the tumor micro-
environment. Histological analysis of human tumors, in
particular CRC, has highlighted the importance of the
combination of immune variables. We have previously de-
scribed these major immune parameters, associated with
survival in colon cancer, as the “immune contexture”
[110]. The immune contexture is defined as the type,
functional orientation, density and location of adaptive
immune cells within distinct tumor regions [111,112]. A
strong lymphocyte infiltration has been reported to be
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clinical outcome. This correlation between the prevalence
of tumor infiltrating immune cells and patient outcome
has been well documented in melanoma, ovarian, head
and neck, bladder, breast, urothelial, colorectal, renal, pros-
tatic, and lung cancer. The majority of studies have dem-
onstrated that high densities of CD3+ T cells, CD8+
cytotoxic T cells and CD45RO+memory T cells are associ-
ated with a longer disease free survival (DFS) and/or im-
proved overall survival (OS) [111].
Derived from the immune contexture, a simple and
powerful immune-classification has been termed the
“Immunoscore”. The Immunoscore (I) is based on the
numeration of two lymphocyte populations (CD3/
CD45RO, or CD3/CD8 or CD8/CD45RO) quantified
within the center of the tumor (CT) and invasive margin
(IM). These parameters provide a scoring system ranging
from Immunoscore 0 (I0), which has low densities of
both cell types in both regions; to Immunoscore 4 (I4),
having high densities of both cell populations in both
regions. The prognostic value of using these immune
criteria was demonstrated in patients with early stage
CRC (AJCC/UICC TNM stage I-II CRC) to predict sur-
vival and relapse. The five Immunoscore groups were
associated with dramatic differences in DFS and OS
(P < 0.0001) [113]. In large cohorts of patients at all can-
cer stages, Cox multivariate analysis shows that tumor
progression and invasion is statistically dependent on
the Immunoscore. In patients who did not relapse, the
density of CD8 infiltrates was inversely correlated with T
stage, whereas in patients with recurrence the number
of CD8 cells was low, regardless of the T stage of the
tumor [114]. Thus, evidence supports the notion to
introduce immunological biomarkers, implemented as a
tool for the prediction of prognosis and response to
therapy. Incorporating the Immunoscore into traditional
classification could result in a greatly improved prognos-
tic and potentially predictive tool [114-116]. To be used
globally in a routine manner, evaluation of a novel
marker should have the following characteristics: vali-
dated for routine testing in clinical laboratory, meet-
ing regulatory standards of analytical validity, simple,
inexpensive, fast, robust, accurate and reproducible,
quantitative, and preferably pathology-based. The
Immunoscore fulfills characteristics of clinically useful
assay.
In an effort to promote the Immunoscore in routine
clinical settings, an international task force was initiated.
The working group, composed of international expert
pathologists, oncologists and immunologists, identified a
strategy for the organization of worldwide participation
by various groups for the validation of the Immunoscore.
The purposes of the Immunoscore worldwide task force
are, to demonstrate the feasibility and reproducibility ofthe Immunoscore, to validate the major prognostic
power of the Immunoscore in routine for patients with
colon cancer stage I/II/III, and to demonstrate the utility
of the Immunoscore to predict stage II colon cancer pa-
tients with high risk of recurrence. Twenty-three (23)
international expert centers agreed to participate in this
visionary enterprise. These participants represent 23
Centers Worldwide from 17 countries including Asia,
Europe, North America, Australia, and Middle East. The
outcome of this international validation effort may result
in the implementation of the Immunoscore as a new
component for the classification of cancer, designated as
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